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Abstract: This review aims to summarize the latest efforts performed in the search for novel chemical
entities such as Toll-like receptor (TLR) modulators by means of virtual screening techniques. This is
an emergent research field with only very recent (and successful) contributions. Identification
of drug-like molecules with potential therapeutic applications for the treatment of a variety of
TLR-regulated diseases has attracted considerable interest due to the clinical potential. Additionally,
the virtual screening databases and computational tools employed have been overviewed in a
descriptive way, widening the scope for researchers interested in the field.
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1. Introduction
Innate immunity is the first defensive wall a pathogen needs to beat to flourish in our body and,
due to the enormous diversity of microorganisms present in our environment, it is composed by a
number of agents able to respond in a highly effective way. Among them, the Toll-like receptors
(TLR) family can recognize a wide variety of pathogens, making them an interesting target to help our
body fight disease [1]. Each TLR is specialized in the recognition of a particular pathogen-associated
molecular pattern (PAMP) arisen from a bacteria or virus. TLRs 1, 2, 4, 5, and 6 are situated primarily
in the plasma membrane, where they recognize bacterial components of microbial cell walls and
membranes, such as lipopolysaccharide (LPS) and lipoteichoic acid from the cell wall, lipoproteins
from the cell membrane, and flagellin. TLRs 3, 7, 8, and 9 are intracellularly located in the membranes
of endosomes and lysosomes, where they bind to microbial nucleic acids, including double- and
single-stranded RNA (dsRNA, ssRNA) from RNA viruses, and DNA from most organisms, including
self-nucleic acids from the host cell [2].
TLR modulators have the potential to be used with different biomedical applications, especially
in the field of infection [3], inflammation [4] and autoimmune diseases [5], but also in central nervous
system (CNS) disorders such as Alzheimer´s disease [6], and cancer [7,8]. However, just a few of
them are currently under clinical development. Therefore, it is imperative to find new chemical
entities as TLR modulators with drug-like properties in order to facilitate their development as drugs.
In the context of drug discovery, virtual screening (VS) techniques have already proved to make
hit identification more goal-oriented, allowing the access to a huge number of chemically diverse
binders (from public and commercial databases) with a relatively low-cost in terms of time and
materials. This computational approach has been subjected to extensive attention and revision over
the years, from the early perspective of being an emerging method [9], until the current time where
new challenges are faced [10–15]. We could say that TLRs are not standard receptors which could
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be approached following classical strategies in drug design. The complexity of the system and the
characteristics of their complexation with the PAMPs make them especially difficult to tackle following
classical procedures in drug design and discovery. This is why TLRs constitute a special case study
in this context. We herein report successful cases of VS approaches that have led to TLR modulators
either with agonist or antagonist activity.
2. Databases
A wide variety of databases containing lead and drug-like small molecules is available for VS
purposes which, inevitably, overlap. Several analysis and comparison studies among the available
compound libraries have been carried out to evaluate molecular uniqueness and database overlapping,
drug-like properties and scaffold diversity [16–18]. Overall, although a substantial overlapping is
found among some of the collections, each database has unique features that may make them more
adequate for a particular VS project, and still a relevant number of unique compounds is found within
each database that makes it worth considering more than one library if possible. Duplicate analysis of
screening libraries comprising the ones cited below showed that 40%–50% of the totality of structure
subjected to analysis were structures exclusive to one supplier library [19,20]. Many of them are
freely available and may possess desirable characteristics such as “drug-likeness”, being the most
popular the “Lipinski Rule of Five” [21]. Others collect chemical structures from natural products or
approved drugs [13]. We here report the databases that have been reported for VS approaches focused
on Toll-like receptors.
2.1. ZINC Database
ZINC (recursive acronym for Zinc Is Not Commercial) is a public access database of commercially
available compounds developed in the Department of Pharmaceutical Chemistry at the University
of California, San Francisco [22]. It contains a constantly growing number of three-dimensional
(3D) structures ready-to-dock from catalogues of major compound vendors with annotated relevant
protonation and tautomeric states, and properties such as size, calculated logP, number of rotatable
bonds, etc. Each molecule also contains purchasability and vendor information [23,24], making this
ZINC’s focus on docking and purchasability the main distinctive characteristic from other databases.
In its latest version, ZINC 15 [25] comprises over 120 million purchasable “drug-like” compounds
together with information regarding target and biological activity, related scaffolds and bioactive
and biogenic compounds (Tanimoto index of 0.6) [25–27]. It also offers other features such as the
possibility to define target-focused libraries and to download subsets of a physical property space
(“fragment-like”, lead-like, drug like subsets).
2.2. NCI Open Database
NCI Open Database is a freely accessible database developed by the Developmental Therapeutics
Program of the National Cancer Institute [28] currently containing >250,000 molecules both from
organic synthesis and natural source extracts [29] that can be downloaded in SDF format. Compounds
can be requested with no fee for research purposes. This database contains a set of compounds that have
been collected by the National Cancer Institute, NIH since 1955, in Human Tumor Cell Line Screens
and from the 1980s in AIDS Antiviral Screen that are not covered due to a confidentiality agreement.
The database contains information about release, structure source and evaluation, calculated/predicted
logP, biological activity, commercial availability, 3D atom coordinates, added hydrogens and also
number of rotatable bonds, stereocenters and bond stereocenters. It provides structures that cannot be
found in any other databases [17].
2.3. ASINEX Database
ASINEX database [30] is a regularly updated commercial collection of compounds which contains
to date: 600,000 screening compounds, 27,000 macrocycles, 23,000 fragments and 7000 building blocks.
Int. J. Mol. Sci. 2016, 17, 1508 3 of 34
The different libraries cover different chemical characteristics and try to address different steps in
the drug discovery process [23]. The broadest collection (Gold collection, 250,000 compounds) offers
high diversity and drug-like space coverage; other libraries are focused on lead-like compounds
(Platinum, in-house collection of 150,000 compounds) and drug-like compounds (ASINEX Synergy,
35,000 compounds) as well as novel scaffolds intended for early stages of drug discovery (Elite libraries,
>900 scaffolds profiled to elude ADMET problems). A fragment set of more than 22,500 compounds
and a natural product-based library, with key structural features of known pharmacologically relevant
natural products (BioDesign, around 13,000 compounds), are also available. In addition, ASINEX offers
targeted libraries (CNS-focused, immuno-oncology-focused, PPIs [31], GPCR, ion channels, kinases,
peptide-mimetics, nucleoside-mimetics, glyco-mimetics, covalent inhibitors, antiviral, carbohydrates,
etc.) and customized screening sets. All the collections can be downloaded in SDF format and they
could be directly purchased.
2.4. SPECS Database
SPECS repository [32] (>240,000 compounds) is composed of novel drug-like small molecules
obtained from academia and research institutes. SPECS’ stock is updated every month and it contains
available compounds that can be purchased upon request. Every molecule in the collection must
fulfill structural characteristics of a biologically active compound, and meet ADMET requirements.
Furthermore, SPECS offers targeted libraries which can be generated by two methods. The first
one analyses the stock database with an in-house predictive software to generate the collections
based on the predicted biological activities (kinase inhibitors, protease inhibitors, signal pathway
modulators, ion channel blockers, GPCR’s ligands, nuclear receptors modulators, antimicrobials,
antivirals, cytostatics, central nervous system ligands). These focused libraries are generated from
predictions based on 2D descriptors and chemical structures of known active compounds, also with a
training set of more than 40,000 chemical structures with confirmed activity for more than 600 specified
activities and therapeutic areas. The second method clusters within the SPECS’ chemical space, or
rather descriptor space (accounting for topological and connectivity information, hydrophobic and
hydrophilic effects, polarizability, and electrostatic interactions). This follows a principal component
analysis and compounds are thus clustered together with hit molecules with reported biological
activity, or from diverse commercial libraries.
2.5. MAYBRIDGE Database
Maybridge [33] Screening Hit Discovery collection (over 53,000 compounds) is a commercial
library of small hit-like and lead-like organic compounds of high diversity (Tanimoto Clustering
at 0.9) [34], that covers ca. 87% of the 400,000 theoretical drug pharmacophores with general compliance
with the Lipinsky rule of five and of good ADMET properties. The HitCreatorTM Collection (selection
of 14,400 of Maybridge screening compounds) aims to represent the diversity of the main collection
covering the drug-like chemical space. Maybridge also offers a fragment library (30,000 fragments), a
hit-to-lead building block collection, and a Ro3 2500 diversity fragment library (2500 fragments) with a
Tanimoto similarity index of 0.66 (based on standard Daylight fingerprinting), assured solubility,
optimized for SPR and Ro3 compliant. It provides special collections of Fluoro, 19Fluoro and
Bromo-fragment libraries.
2.6. LIFE CHEMICALS Database
LIFE CHEMICALS [35] holds a commercial compound collection for High Throughput Screening
(HTS) of 1,213,000 (431,000 in stock from distinctly different 2800 scaffolds) lead-like and drug-like
new chemical entities selected taking into account diversity, Lipinski’s rules [21] and Veber
criteria [36]. Furthermore, it offers several different diversity libraries on demand: building
blocks, fragment- and scaffold-based libraries and different kinds of targeted/focused libraries
(natural product-like compounds, covalent inhibitors, epigenetics-related compounds, PPI inhibitors,
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transmembrane receptors binders, nuclear receptor modulators, transporters, enzymes targeted
compounds, etc.) [37–39]. The collection is available both as MDL SD (.sdf) or MDL ISIS (.db) files.
2.7. ENAMINE Database
ENAMINE [40] provides several different commercial collections of compounds for screening:
the HTS collection (>1,720,000 compounds) represents a highly diverse set of chemotypes designed
from in-house research experience, while the Advanced Collection (>278,000 compounds) is intended
for lead discovery. The latter set of compounds has been designed according to lead-like properties
(MW ≤ 350, cLogP ≤ 3, and rotB ≤ 7) and/or valuable pharmacophores such as carboxylic, primary
amino and amide groups. This database also provides diversity sets derived from the screening
collection: a drug-like set (20,160 compounds, Lipinski [21] & Veber’s [36] rules-compliant with no
reactive functional groups), a pharmacological diverse set (10,240 drug-like compounds clustered
by activities from biologically relevant chemical space) and a 3D diversity set (50,240 compounds
from conformational analysis and shape clustering of HTS collection) as well as targeted libraries
(CNS, antibacterial, ion channel, kinase and Lipid GPCR libraries), fragment libraries (general, golden
-multi-purpose fragment tool library-, covalent, sp3-rich, PPI, fluorinated and brominated fragments)
and Enamine’s REAL database which is a virtual collection of over 2 × 107 structures of various novel
compounds that can be successfully synthesized. This collection can be filtered according to specific
criteria (diversity, scaffold type, MW, drug-likeness, Lipinski’s rule-based, ADMET properties, etc.).
The structure data files from various regularly updated collections of compounds can either be directly
downloaded from the webpage in MDL SD (.sdf) or MDL ISIS (.db) formats or obtained by request.
2.8. CHEMBRIDGE Database
ChemBridge [41,42] encompasses one million drug-like and lead-like compounds in
two non-overlapping collections of respectively 460,000 and 620,000 compounds, that cover different
chemical spaces and that can be customized to create diversity libraries, targeted libraries (KINASet,
CNS-Set, and IONSet libraries) and fragment libraries, which can be purchased upon request.
In particular, the EXPRESS-Pick library intends to embrace broad chemical spaces and offers different
classes of compounds of high diversity with analogues to assist in structure–activity relationship
(SAR) studies, and the CORE library undertakes non-covered chemical spaces by other libraries and is
enhanced with a large number of sp3-rich scaffolds. The screening libraries can be downloaded as
MDL SD (.sdf) or MDL ISIS (.db) files.
3. Virtual Screening Protocols and Techniques
General strategies for a VS protocol include several steps that are summarized in Figure 1.
The availability of the 3D coordinates of the target is mandatory, either from X-ray crystallography,
NMR or homology modeling. Prior knowledge about the ligand binding site may help in the
identification of proper binders although, in some approaches, the search for novel binding pockets
can be an additional interesting—and challenging—element in the drug discovery process. In this
review, we will not focus on these aspects but rather describe the computational protocols employed,
so far, to perform virtual screening on Toll-like receptors. We will go over database processing,
pharmacophore generation and, finally, docking tools successfully used for VS in TLRs (Table 1).
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Figure 1. Summary of the virtual screening (VS) protocols applied for the search for novel Toll-like 
receptors (TLR) modulators: access to databases and preparation/filtering of small-molecules; 
pharmacophore generation; docking calculations; selection of candidates; experimental testing, and 
final identification of drug candidates. 
Figure 1. Summary of the virtual screening (VS) protocols applied for the search for novel Toll-like
receptors (TLR) modulators: access to databases and preparation/filtering of small-molecules;
pharmacophore generation; docking calculations; selection of candidates; experimental testing, and
final identification of drug candidates.
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3.1. Database Processing and Inclusion of Decoys
Database processing constitutes a fundamental step in VS approaches. It is crucial to generate the
proper chemical library, with the adequate geometries, ionization states, conformations, tautomers,
etc. Furthermore, it is very important to discard any molecule that will not be a good candidate in the
further steps of the VS study in relation to the particular system on hand. A good database processing
will assure a rigorous and well-conducted virtual screening, as well as avoiding computational costs
and identification of unsuitable drug candidates.
3.1.1. LigPrep
LigPrep [43], a software created by Schrödinger LLC, is a collection of tools designed to prepare
high quality, all-atom 3D structures for large numbers of drug-like molecules, starting from 2D or 3D
structures. LigPrep starts by converting the input structure files to Maestro [44] format. The LigPrep
process consists of a series of steps that perform conversions, apply corrections to the structures,
generate variations on the structures, eliminate unwanted structures, and optimize the geometry.
LigPrep produces a single low-energy 3D structure with defined chiralities for each processed input
structure, and it can also produce a number of structures from each of the starting geometries with
varying ionization states, tautomeric forms, stereoisomers, and ring conformations. Additionally,
LigPrep offers the option to eliminate molecules from the collection to be screened using various criteria
including molecular weight or quantity and types of functional groups composing the molecule.
3.1.2. OMEGA
OMEGA [45] is a software program created by OpenEye Scientific Software (Santa Fe, NM, USA)
that generates conformations of molecules. The process used by OMEGA relies on the construction
of a database of fragments, from which the molecule will be assembled, and the derivation of a
torsion library.
To quickly sum up the process, OMEGA starts by preparing the fragment database by fragmenting
a very large collection of compounds into contiguous ring systems and small linear linkers. Then, each
fragment undergoes an optimization process in order to generate one or more 3D conformations per
fragment. The next step is a torsion sampling library generation process, determining the bonds that
may freely rotate, and assigning them a list of possible dihedral angles to each rotatable bond, using
SMARTS [46] matching. All torsions are altered by 120 and 180 degrees, and a RMSD calculation is
performed. The resulting conformers are placed into a list ranked by energy, and entire structures are
assembled by combining the lowest energy set of fragments, and the energy window of the global
minimum structure. A final ensemble is selected by sequentially testing the conformers using the
RMSD cutoff (user-defined). It is populated up to the user defined maximum ensemble size limit, or
until the list of low energy conformers is exhausted.
The third step is the generation of 3D structures, fragmenting the molecular graphs of the
conformers in the same manner as the fragment database, and comparing them to each other.
The fragments are then assembled into the parent molecule by overlapping fragments using geometric
and chemical rules, providing one or a small number of initial conformations for the molecule. Then,
a large ensemble of conformations without internal clashes or duplicates resulting from common
symmetries is generated, comparing every rotatable bond in the previous conformers to the torsion
library and scoring them. Minimization is not performed during the entire process to avoid the
production of highly folded conformations not reflective of the one found in solution or bound to
a receptor.
3.1.3. AutoDockTools
AutoDockTools (ADT) [47] is the graphical interface implemented within the Python Molecular
Viewer to make AutoGrid and AutoDock (both are required to be used) widely accessible tools [47–49].
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It facilitates the formatting of input molecule files, with a set of methods that guide the user through
protonation, calculation of charges, and specification of rotatable bonds in the ligand and the protein.
As a brief outline of the preparation process, the ligand is loaded into the graphical interface, and ADT
prepares it for AutoDock docking program. Polar hydrogens are added, charges are calculated, and
nonpolar hydrogens are merged with the heavier atoms to which they are attached. If the ligand file
presents no charges, ADT will compute Gasteiger charges. Then, AutoDock atom types are assigned to
each atom. Regarding the ligand preparation for the virtual screening, it is important to consider the
flexibility of the ligands. For this purpose, ligand flexibility is assigned in several steps. First, a root
atom is chosen, which will act as the fixed position during coordinate transformation in the docking
simulation. To find the optimal atom, the number of atoms in each branch is evaluated, and the root
atom that minimizes the size of the largest branch is chosen. However, the ligand flexibility can be
limited. As a limitation, each step in ADT has to be launched manually, one by one, as well as the
preparation of each ligand. However, it is possible, with simple scripts, to do it automatically.
3.1.4. MUBD-Decoymaker
The use of unbiased benchmarking sets is an important aspect of VS validation. Several decoy sets
are available and many of them have been used to validate docking scoring functions. In particular,
MUBD-Decoymaker [50] has been used for the virtual screening of potential ligands of TLR8 [50].
MUBD-Decoymaker is an unbiased computational method to build benchmarking sets for ligand-based
virtual screening. By submitting molecules and decoys to the computational tool, the program will
rank them, ensuring chemical diversity of ligands, maintaining the physicochemical similarity between
ligands and decoys, making the decoys dissimilar in chemical topology to all ligands to avoid false
negatives, and maximizing spatial random distribution of ligands and decoys.
3.2. Pharmacophore Generation
Pharmacophore-based strategies have also been used for VS in the context of searching for
TLR modulators, LigandScout and ROCS being the most used ones. Other pharmacophore model
generation software packages are: Catalyst [51], MOE [52] and Phase [53,54]. When lacking 3D
structure of the corresponding TLR, ligand-based pharmacophore generation can be a very useful tool
for the identification of putative hits. The combination with structure-based pharmacophores provides
more robust models for hit identification.
3.2.1. LigandScout
LigandScout [55] allows the generation of structure- and ligand-based pharmacophore models that
can be used in VS. A key characteristic of LigandScout, that distinguishes it from other pharmacophore
modeling packages, is that it allows the definition of multiple features per heavy atom. These chemical
features are used to perform pairwise alignments of pharmacophores and molecules [50]. For the
structure-based approach, the program starts from the macromolecule structure with a bound ligand,
either from a co-crystal structure or from a predicted binding pose from docking calculations.
The structure-based pharmacophore modeling relies on the automated extraction and interpretation
of the key ligand features important for the interaction with the receptor (planar ring detection,
assignment of relevant functional group patterns, hybridization state determination, and Kekulé
pattern assignment) [55]. Thus, the 3D pharmacophore model contains the chemical features that
represent the key interactions with the macromolecule aligned in 3D space, together with a series of
excluded volume features defining areas sterically hindered by the macromolecular environment and
the shape of the binding site. The model can be used for VS within LigandScout or be exported to
other external applications (Catalyst, MOE, and Phase).
Ligand-based pharmacophores can also be created from a set of known active ligands in the
absence of a receptor structure. Molecular flexibility of every molecule in the set is taken into account
(OMEGA) [55] and each molecule is ranked according to its number of conformations. Chemical
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features and exclusion volumes spheres are defined and weighted. Intermediate pharmacophore
models are generated through the molecular alignment of selected conformations. These intermediate
pharmacophore models are ranked using different scoring functions and sequentially aligned to every
conformation of every molecule of the set. New intermediate combined feature pharmacophores
are generated until at least three common chemical features are identified throughout the whole
alignment and interpolation process. Exclusion volume spheres have only been included in the newest
version of the program. The directionality of donor/acceptor groups is not taken into account since
there may be ambiguity in positioning, given the absence of the receptor structure. LigandScout
provides three geometric types of features: vector (H-bond acceptor, H-bond donor, metal binding
location for Iron, Magnesium and Zinc atoms), point (hydrophobic interactions, negative ionizable
areas, positive ionizable areas, exclusion volume) and plane feature (aromatic ring, plausible pi–pi or
cation–pi interactions). The pharmacophore models thus created can then be used in various external
VS applications.
Pharmacophore-based virtual screening using LigandScout has been successfully applied to the
identification of a novel TLR2 inhibitor in the µM range [56]. A structure-based pharmacophore model
of the TLR2 lipopeptide binding site, based on energetically favored potential interactions identified
by MIFs (Molecular Interactions Fields) calculations using MOE package [57], was created with the
following relevant features: one H-bond acceptor with the NH group of Phe349, one H-bond donor
interaction with the carbonyl oxygen of Leu350, and two hydrophobic areas (one covering the region
of Phe325, Ile319 and Val348, and a second one around residues Leu328, Leu266, Phe295, Phe284, and
Ile314 of the TLR2). Exclusion volumes were added and the 3D pharmacophore was used for virtual
screening with LigandScout 3.0 using standard settings against a collection of 2,831,238 commercially
available compounds from different vendors. Among the compounds that fitted the pharmacophore,
the 150 compounds with the highest pharmacophore fit score were submitted to docking studies
using GoldSuite [58]. A subsequent minimization of the binding poses within the binding site was
performed with the MMFF94 force field implemented in LigandScout. Five compounds were finally
selected for biological studies and one compound (code MolPort-001-796-266, Table 2) was confirmed
as TLR2 antagonist. For TLR8 [59], while LigandScout was also used to obtain pharmacophore models
within a sophisticated protocol to optimize VS of TLR8 agonists (see Section 4.5).
3.2.2. Rapid Overlay of Chemical Structures (ROCS)
ROCS (Rapid Overlay of Chemical Structures) [60] is a powerful tool for virtual screening which
identifies active compounds by shape comparison, based on the idea that molecules have similar
shape if their volumes overlay well and that any volume mismatch is a measure of dissimilarity. It is a
shape-based superposition method and uses a smooth Gaussian function to represent the molecular
volume. The sensitivity is also represented by using hard spheres cut-offs as in many other shape
overlay and pharmacophore matching methods. ROCS considers only the heavy atoms of a ligand,
ignoring hydrogen atoms. Conformational flexibility is not implemented but it can be taken into
account by using precomputed ensembles of conformers (for instance, with OMEGA program [55]).
Although ROCS is primarily a shape-based method, chemical definitions specified by the user
can be included into the superposition and similarity analysis process, facilitating the identification of
those compounds similar in both shape and chemical features. By default, ROCS compares molecules
based purely on their best shape overlap, quantified by their ShapeTanimoto score. Then, the program
ranks the database molecules based on their ShapeTanimoto to the query molecule. It was found that
adding the so-called “color score” to the ShapeTanimoto score for the appropriate overlap of groups
with alike properties (donor, acceptor, hydrophobe, cation, anion, and ring), and then ranking this
summed score, the virtual screening performance considerably improved. Cations and anions can
be defined according to an implicit pKa model such that the same group had the same protonation
state regardless of the protonation state set in the input structure definition. This overlay is then
subsequently scored using the sum of ShapeTanimoto for the overlay and the color score (the so-called
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“combo score”). Customization or target-specific information can be incorporated by adding a term to
the color force field file that rewards overlay of specific functional groups. ROCS alignments have also
other type of applications: 3D-QSAR, SAR analysis, understanding of scaffold diversity and detection
of common binding elements. ROCS alignments to crystallographic conformations have also been
useful in pose prediction in the absence of a protein structure [61]. This tool has also been used for
a probabilistic framework for structure- and ligand-based virtual screening [62], for use in analog
searching and lead hopping [63], and also for comparison of topological, shape and docking methods
in virtual screening [64].
In the context of this review, ROCS has been used together with LigandScout, for pharmacophore-
based protocols applied to VS on TLRs, specifically on TLR2, TLR7 and TLR8 (see below). In the case of
TLR7 [65], since no crystal structure of the target was available, a ligand-based approach was followed
by using ROCS to obtain new compounds with similar activity as a query compound. The ZINC
database was prepared with OMEGA program. Two query compounds were obtained from two
well-known TLR7 ligands. The 3D ligand-based VS was carried out with the prepared ZINC database
and the compounds were ranked with the “TanimotoCombo” score (considering shape and atom
type). Six new compounds with three new chemical scaffolds were identified as TLR7 antagonists with
activities within the µM range (Table 2). In the case of TLR8 [59], in order to generate ROCS queries,
the authors performed an alignment of six crystal ligands as initial molecules. The results were ranked
using the “ShapeTanimoto” and the “TanimotoCombo” scores. Ligand-based VS in TLR2 has also
been performed with ROCS [56]. Using this approach, several novel TLR2 antagonists were identified
in the low-µM range. A shape- and feature-based search was run using three known TLR2 modulators
as separate queries against the open NCI database using ROCS default settings. The resulting hits
with the highest shape and feature overlap were selected for biological testing where four compounds
showed inhibitory activity. Two of these four confirmed antagonists were used as query along with two
of the initial queries for a second shape- and feature-based search, this time against a larger collection
of compounds and an additional docking step using GOLD docking program. After this second search,
three additional antagonists were confirmed. More details about this work can be found in Section 4.
3.3. Docking Tools for Virtual Screening (VS)
Molecular docking is a well-established method to investigate how a ligand interacts with its
receptor. It integrates an automated computer algorithm that determines how a compound may
bind in the active site of a target (binding mode and ligand–receptor interactions) and that tries to
predict how tightly it binds (prediction of the binding energy), revealing the electrostatic and steric
complementarity between the protein and the ligand. Other current challenges in structure-based drug
design, outside the scope of this review, include the inclusion of the protein flexibility, active water
sites, searching of binding pockets, among others [66–68].
Nowadays, most of the docking programs are characterized by (i) the specific method to treat
ligand flexibility [69], which can be divided into three categories: systematic methods (incremental
construction and conformational search); random or stochastic methods (Monte Carlo, Genetic
Algorithms and Tabu search); and simulation methods [70] (molecular dynamics and energy
minimization); (ii) the scoring function [69], classified into three categories: (ii.a) force field-based
scoring functions [71], where a classic force field is employed to compute the noncovalent ligand-target
interactions, such as van der Waals and electrostatic energies (they are often augmented by a GB/SA
or PB/SA term in order to account for the solvation effect); (ii.b) empirical scoring function [72,73],
where the overall binding free energy is calculated by adding the contributions from several energetic
terms, including hydrogen bond (H-bond) interaction and hydrophobic interaction (the weighting
factors of all terms are calibrated from a set of known complexes with experimentally determined
structures and binding affinities); and (ii.c) knowledge-based (KB) scoring functions [74,75], where the
ligand–target interactions are computed as a sum of distance-dependent statistical potentials between
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the ligand and the target (only the structural information of ligand-target complexes is needed, which
is being accumulated rapidly due to structural biology advances).
Table 1. Overview of the docking programs employed for virtual screening (VS) in Toll-like receptors
(TLRs) mentioned in this review. ST: Stochastic; SYS: Systematic; E: Empirical; FF-based: Force field
based; K-based: Knowledge-based.
Program Ligand Flexibility Method Scoring Function Society
Type Algorithm Type Name Name (Availability) Website
AutoDock
VINA ST
Iterated Local
Search global
optimizer
Hybrid
E/K-based -
The Scripps Research
Institute, la Jolla (Free) [76]
DOCK SYS
Incremental
construction
Anchor-and-Grow
Algorithm
FF-based DOCK 3.5score
University of California San
Francisco (Free) [77]
FlexX SYS
Incremental
Reconstruction
Algorithm
E SCORE1 BioSolveIT (Commercial) [78]
Glide SYS Exhaustive SearchAlgorithm E GlideScore Schrödinger (Commercial) [79]
GOLD ST Genetic Algorithm
FF_based
E
K-based
E
GoldScore
ChemScore
ASP
ChemPLP
University of Sheffield,
GlaxoSmithKline plc and
CCDC (Commercial)
[80]
ICM ST
Pseudo-Brownian
sampling and local
minimization
E
K-based
ICMScore
PMF MolSoft (Commercial) [81]
Surflex-Dock SYS
Incremental
Reconstruction
Algorithm Whole
Molecule Approach
E Re-parameterizedHammerhead Tripos (Commercial) [82]
Here, we briefly outline the most used docking tools for virtual screening in the TLRs field, which
are Glide, AutoDock VINA, GOLD, Surflex-dock, FlexX, ICM, and DOCK (Table 1). The reader is
referred to the original papers for a detailed account.
3.3.1. Glide
Glide is a commercial docking program provided by Schrödinger [83–85]. It uses a hierarchical
series of filters to search for possible locations of the ligand in the active-site region of the receptor.
It has a systematic method to treat ligand flexibility, with an exhaustive search algorithm. The Glide
protocol is intuitive and relies on four steps: the ligands and protein preparation, the receptor grid
generation, and the docking process. Before launching the docking step, Glide has to generate a
grid that represents the shape and the properties of the receptor, using several different sets of fields
that provide progressively more accurate scoring of ligand poses. The grid permits to dock only the
relevant region of the receptor, thus saving calculation time.
Regarding the last point, the full docking VS workflow includes three docking stages: HTVS,
SP (Standard Precision) and XP (Extra Precision). The first stage performs High Throughput Virtual
Screening (HTVS) docking. It is intended for rapid screening of a very large number of ligands and
has much more restricted conformational sampling than SP docking. The second stage performs SP
docking. It is appropriate for screening ligands of unknown quality in large numbers. The third
stage is the XP docking and scoring. It is a more powerful and discriminating procedure using
an implementation of a modified and expanded version of the ChemScore scoring function, called
GlideScore [84] and categorized as an empirical scoring function. Glide can be used to perform
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virtual screening, accurate binding mode precision and, furthermore, Glide exhibits excellent docking
accuracy and high enrichment across a diverse range of receptor types.
3.3.2. AutoDock VINA
AutoDock VINA (Vina is not AutoDock) is an open-source molecular docking program [86].
It has no graphical interface but it is compatible with MGLTools [87]. However, although MGLTools
need other files, such as AutoDock and AutoGrid parameter files (GPF, DPF) and grid map files,
VINA does not need them. All it requires is the 3D structures of the molecules to be docked and
the specification of the search space including the binding site. One limitation in VINA is that the
maximum number of predicted binding poses is limited to 20 per ligand. AutoDock VINA uses
a hybrid scoring function. It is inspired by X-score [88] and tuned using the PDBbing [89,90] and
extracting empirical information from both the conformational preferences of the receptor-ligand
complexes and the experimental affinity measurements. It is both an empirical and a knowledge-based
function. Regarding the optimization algorithm, the Iterated Local Search global optimizer is used,
and to treat ligand flexibility and optimization, VINA uses a stochastic method with the Iterated Local
Search global optimizer [91,92].
3.3.3. GOLD
GOLD (Genetic Optimization for Ligand Docking) [93–95] is a commercially available docking
program produced from the collaboration between the University of Sheffield, GlaxoSmithKline plc
and Cambridge Crystallographic Data Center. It is an automated ligand docking program that uses
a stochastic method with a Genetic Algorithm to explore the full range of ligand conformational
flexibility with partial flexibility of the protein, and it satisfies the fundamental requirement that the
ligand must displace loosely bound water on binding.
In order to address ligand conformational flexibility in the binding pocket, GOLD offers a choice
of several scoring functions: GoldScore [94], ChemScore [73], ASP [96,97], ChemPLP [98,99] and also a
user-defined score. GoldScore is categorized as a force field-based scoring function. It is the original
scoring function provided with GOLD, and has been optimized for the prediction of ligand binding
positions rather than binding affinities. It takes into account factors such as H-bonding energy, van der
Waals energy, metal interaction and ligand torsion strain. ChemScore is an empirical scoring function
which incorporates, contrary to GoldScore, a term (dG) that represents the total free energy variation
that occurs upon ligand binding. It also incorporates a protein-ligand atom clash term and an internal
energy term. Unlike GoldScore, ChemScore was trained by regression against measured affinity data,
although there is no clear indication that it is superior to GoldScore in predicting affinities. ASP (Astex
Statistical Potential) is a knowledge-based scoring function that can be compared to PMF [96,100] and
DrugScore [75,101]. It uses an atom-atom distance potential derived from a database of protein-ligand
complexes. ASP incorporates some ChemScore terms. Finally, ChemPLP is an optimized empirical
scoring function. It uses the ChemScore H-bonding term and multiple linear potentials to model van
der Waals and repulsive terms. In recent issues, it has been shown that it outperformed the previous
scoring functions for both pose prediction and virtual screening purposes [102]. ChemPLP is now the
default scoring function in the GOLD recent releases.
3.3.4. Surflex-Dock
Surflex-Dock [103,104] is a commercially available docking program distributed by Tripos and
based on an idealized binding site ligand called “protomol” [105] used as a target to generate putative
poses of molecules or molecular fragments relying on a molecular similarity method, which are scored
using a re-parameterized Hammerhead empirical scoring function [106] with additional negative
training data [107]. Like Hammerhead, Surflex-Dock has one mode that uses a systematic incremental
construction search approach, to treat ligand flexibility. Additionally, Surflex also uses the whole
molecule approach.
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3.3.5. FlexX
FlexX [108] is a commercial based docking program provided by BioSolveIT included in the
LeadIT package. To handle ligand flexibility, FlexX uses a systematic method with an incremental
reconstruction algorithm, where base fragments are identified first, and then, placed into the receptor
active site, using a hashing technique. The whole ligand is thus constructed by adding the remaining
components step by step selecting each time the optimal partial solution. The scoring function is
SCORE1 [109] which is an implemented empirical Böhm function that uses the de novo design program
called LUDI [110]. The function takes into account entropic, H-bonding, ionic, electrostatic, aromatic
and lipophilic interactions terms.
3.3.6. ICM
ICM (Internal Coordinate Mechanic) is a commercially available docking program provided by
MolSoft and based on a stochastic pseudo-Brownian sampling and local minimization [111]. ICM can
read, build, convert, refine, analyze and superimpose molecules, plus providing target evaluation to
generate 3D models. The ICM docking algorithm, a Metropolis Monte Carlo energy minimization [112],
is based on global optimization of the energy function describing the intra-molecular ligand energy
and the total interaction energy of the ligand-receptor complex. Conformational sampling is based on
the biased probability Monte Carlo (BPMC) procedure [113] which randomly selects a conformation
in the internal coordinate space and then moves toward a new random position independent from
the previous one but according to a predefined continuous probability distribution to find the global
minimum of the energy function.
Two scoring functions (ICM Score and PMF Score) [114,115] based on two diverse approaches of
evaluating ligand–receptor interactions are implemented in the ICM docking software. The ICM
Score is an empirical scoring function based on calculation of physiochemical properties of the
receptor–ligand complex [116]. The ICM Score is calculated as the weighted sum of scores describing
the energy terms evaluated during docking simulations (Grid score, H-bond score, electrostatic score,
and surface score). The PMF (Potential of Mean Force) Score is a statistical knowledge-based scoring
function based on structural information of known protein–ligand complexes [96].
3.3.7. DOCK
DOCK [77,117,118] is a docking software free for academic use, produced at the University of
California San Francisco (UCSF). To handle ligand flexibility, DOCK uses a systematic method with an
incremental construction algorithm called anchor-and-grow. In this strategy, the largest rigid portion
of the ligand (called anchor) is identified and oriented in the active site. The flexible portions of the
ligand are then systematically grown from the anchor, clustering at each layer of growth to maximize
geometric diversity, until a full molecule is formed. It realizes a superimposition of the ligand onto
a negative image of the binding pocket. DOCK uses several scoring functions, the main one being
a force field-based scoring function called DOCK 3.5 score, and additional scoring options during
minimization, electrostatics calculations, ligand conformational entropy corrections, ligand/receptor
desolvation, molecular dynamics simulation capabilities, and other options.
4. Virtual Screening in Toll-Like Receptors: TLR2, TLR3, TLR4, TLR7 and TLR8
This section is intended to review the VS studies reported to date in the TLR modulators field.
A brief outline about the particular TLR is provided to facilitate the understanding and better follow
the work performed. VS protocols and different computational steps are detailed, together with the
main results from biological testing. Tables 2–4 contain some of the chemical structures of the main
TLR modulators identified so far by VS approaches.
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4.1. Virtual Screening Studies in TLR2
TLR2 heterodimerization either with TLR1 or TLR6 mediates specific ligand recognition of
bacterial lipopeptides [47]. The X-ray crystallographic structures of both extracellular heterodimers
have been resolved assisted by homology modeling in the past few years in complex with the
triacylated [119] and diacylated [120] synthetic lipopeptides Pam3CSK4 and Pam2CSK4, respectively
(Figure 2). The crystal structure of the TLR2/TLR1 heterodimer [119] with the triacylated lipoprotein
revealed that the two ester-linked lipid chains are inserted into the large TLR2 pocket in extended
conformation, and the remaining amide-bound lipid chain is inserted into a narrow channel present in
TLR1. The binding site is mainly composed of hydrophobic residues from Leucine-rich repeat (LRR)
modules 9–12 in both receptors. The peptidic head establishes contacts with polar groups from Phe349
from TLR2, and Gly313 and Gln316 from TLR1. Interestingly, in the case of the (mouse) TLR2-TLR6
heterodimer co-crystalized with the diacylated lipopeptide, the TLR2–lipid interaction and strong PPIs
seem to be the prime force for heterodimerization and signaling since the TLR6 channel is shortened
by the presence of the bulky side chains from Phe343 and Phe365. A H-bond between the Phe319
(TLR6) backbone and the first peptide bond of the lipopeptide is herein detected.
Regarding the application of VS tool for the finding of novel TLR2 modulators, Zhong et al. [121]
report the identification of a natural product-like inhibitor of TLR2/TLR1 heterodimerization (code
ZINC12899676, Table 2) following a structure-based VS strategy, through the docking of a collection of
natural products and natural product-like compounds from ZINC database (>90,000 compounds) to a
TLR2/1 ectodomain model based on the TLR2/TLR1/Pam3CSK4 crystal structure (PDB-ID: 2Z7X).
The model was minimized using the BPMC algorithm [113,122], and grid potential maps accounting
for hydrogen-bonding, van der Waals, hydrophobic, and electrostatic interactions were calculated.
Flexible ligand docking was performed using the virtual library screening module in the ICM-Pro
program [123] at the TLR2/TLR1 heterodimeric interface. The 17 best ranked solutions according
to the Full ICM Score compounds were selected for biological testing. Among these 17 compounds,
compound ZINC12899676 (Table 2) could decrease the secretion of pro-inflammatory cytokines TNF-α
and IL-6 in RAW264.7 macrophages stimulated with the most studied TLR2/TLR1 agonist, Pam3CSK4.
It showed that it could reduce the secretion of TNF-α by 44% over the concentration range of 0.25 to
4 mM, with an IC50 value of ca. 6.1 mM, and the secretion of IL-6 by 56% on the concentration range of
0.25–2 mM, with an IC50 value of ca. 1.9 mM, displaying similar potency to the only other TLR2/TLR1
small molecule antagonist reported to date (CU-CPT22) [124,125] with no cytotoxic activity being
detected. Compound ZINC12899676 also demonstrated its ability to reduce the phagocytic activity of
RAW264.7 cells.
The mechanism of the antagonist activity exhibited by compound ZINC12899676 is proposed
to be by displacement of the synthetic lipopeptide Pam3CSK4, as shown by docking studies where
two key H-bonds were identified: one between the carbonyl oxygen of the oxalamide motif and the
Phe312(TLR1) NH group, and a second one between the amide NH group and the carbonyl CO group
of Phe325 from TLR2. Complementary biological and biophysical tests corroborated this possible
mechanism of action. A fluorescence polarization assay demonstrated the ability of ZINC12899676
to disrupt Pam3CSK4-mediated TLR1/TLR2 heterodimerization in a dose-dependent manner, with
an IC50 value of ca. 7.2 mM. An immunoprecipitation assay was used to confirm the inhibitory
effect on lipoprotein-induced TLR1/TLR2 heterodimerization exhibiting similar potency to reference
compound CU-CPT22. Compound ZINC12899676 could attenuate NF-κB-luciferase reporter assay
in RAW 264.7 cells with greater potency than CU-CPT22, and in HEK293T cells transfected with
pZERO-TLR1, pCMV-Flag-TLR2 and pNF-κB-Luc, and was able to downregulate IkBα and IKKα/β
phosphorylation and IkBα expression in cellulo.
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Other interesting results in this field are the work reported by Murgueitio et al. [56]. The authors
report the analysis of TLR2 monomer to predict and locate ligand binding sites using Q-SiteFinder and
Site Finder applications in MOE. A subsequent structure-based strategy was followed by centering
the VS on the lipopeptide binding site sub-pockets P1-P3. A 3D-pharmacophore model was then
constructed using LigandScout [55] revealing a hotspot for H-bond acceptors with the backbone
nitrogen atoms from Phe349 and Leu350, and for H-bond donors with the carbonyl oxygen of Leu350.
Two hydrophobic areas, defined as HYD1 (Ile319, Phe325, and Val348) and HYD2 (Leu266, Phe284,
Phe295, Ile314, and Leu328), were also characterized. This model was validated and used to screen a
library of more than 2,800,000 commercially available compounds from different vendors (ASINEX,
Life Chemicals, Maybridge, ChemBridge, ENAMINE HTS Collection, and SPECS) with the help
of LigandScout.
One hundred and fifty compounds with the highest pharmacophore fit score were docked
into the TLR2 binding pocket using GOLD [93–95] and, after careful visual inspection, five of
them were selected for biological testing on a NF-κB reporter assay in the cell line HEK293-TLR2.
Compound with code MolPort-001-796-266 (Table 2) exhibited antagonistic activity, and the IC50
value was measured in human monocytes obtaining µM values (decrease in TNF-α production:
IC50 (µM) TLR2/1 = 28.01 ± 1.23, and IC50 (µM) TLR2/6 = 10.91 ± 1.38). Its presumed binding mode
was studied by means of docking techniques into the TLR2 binding site, displaying the following
key interactions: the nitrogen of the sulfonamide group forms a H-bond with the carbonyl oxygen
from Leu350; H-bonds are also formed between the backbone NH groups of Phe349 and Leu350 and
the sulfonamide oxygen of the ligand; the chlorine substituent of the sulfamoylbenzamide moiety
establishes hydrophobic contacts with Ile319, Phe322, Phe325, Val348, and Phe349 residues located
deep inside the TLR2 pocket (Figure 2).
A ligand-based strategy was followed using a shape- and feature-based similarity screening
assisted by ROCS and using three reported small-molecule TLR2 signaling modulators (compounds A & B,
Figure 2) [31] and E567 (Figure 2) [126] against a NCI compound library of 260,071 compounds.
Five hundred hits arose from the VS and, after visual inspection, 39 were selected for biological
testing. Out of them, four exhibited antagonist activity (hit rate: 10%): compounds ZINC16769362 and
ZINC398557 (that were identified from compound B as query structure) and compounds ZINC1758666
and ZINC585632 (from E567 as query) (Table 2).
The same procedure was repeated using compounds A, B (Figure 2), ZINC16769362, and
ZINC585632 (Table 2) as queries, this time against the collection of more than 2,800,000 commercially
available compounds used in the structure-based approach. From this procedure, 22 compounds
were selected for biological testing and three of them displayed antagonistic activity (Z416323354,
MolPort-009-737-181, and MolPort-002-914-354, Table 2). Compounds were also tested for
TLR2-specificity and toxicity, and the decrease of pro-inflammatory cytokine TNF-α was evaluated in
human monocytes.
Additional computational docking studies of ZINC16769362, which showed the lowest IC50, were
carried out showing that the ligand is embedded into a narrow sub-pocket at the end of the binding site
thus interfering with lipopeptide binding. The binding pose is mainly stabilized by H-bonding between
the NH groups of the ligand and the CO groups from Asp305 and Pro306 backbones. Additional
hydrophobic contacts are provided by the naphthyl group with lipophilic side chains of the pocket
residues. The substitution pattern of the phenyl moiety was shown to be crucial for activity, since
compounds with other pattern of substitution were inactive, as well as the presence of aromatic rings,
as compounds with aliphatic rings were inactive. Overall, these results shown to be very promising
for the identification of several novel TLR2 antagonist with activity in the µM range by using virtual
screening techniques.
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Table 2. 2D Chemical structure of TLR2 modulators identified by VS techniques and mentioned in this
review. The database codes are provided. a MolPort is a supplier of chemicals included in several VS
databases (www.molport.com).
TLR2/TLR1 TLR2/TLR6
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ZINC: ZINC1758666 [56] 
NCI: Plated 2007: 17379 
TLR2/1 & TLR2/6 inhibitor 
C29L (O-vanillin) [127] 
TLR2 TIR domain inhibitor 
ZINC: ZINC585632 [56] TLR2/1 & TLR2/6 inhibitor 
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hydrophobic contacts with Ile319, Phe32 , Phe325, Val348, and Phe349 residues located deep inside the 
TLR2 pocket (Figure 2). 
A ligan -based strategy was followed using a shape- nd feature-based simila ity screening 
assisted by ROCS a d using three reported small-molecule TLR2 si naling m dulators (compounds 
A & B, Figure 2) [31] and E567 (Figure 2) [126] against a NCI compound library of 260,071 compounds. 
Five hundred hits arose from the VS and, after visual inspection, 39 w re selected f r biological 
testing. Out of them, four xhibi ed antagonist activity (hit rate: 10%): compounds ZINC16769362 
and ZINC398557 (that were dentified from compound B as query structure) and compounds 
ZINC1758666 and ZINC585632 (from E567 as query) (Table 2). 
Table 2. 2D Chemi al structure of TLR2 modulators i entified by VS techniques and mentioned in 
this review. The databa e codes are provided. a MolPort is a suppli r of chemicals included in several 
VS databases (www.m lport.com). 
TLR2/TLR1 TLR2/TLR6
  
3D structure from PDB-ID 2Z7X 3D structure from PDB-ID 3A79 
 
 
ZINC: ZINC12899676 [121] 
TLR2-TLR1 heterod merization inhibitor 
ENAMINE: Z416323354 [56] 
MolPort a: MolPort 009-315-475 
TLR2/1 & TLR2/6 inhibitor 
 
 
MolPort a: Molport 001-796-266 [56] 
TLR2/1 & TLR2/6 inhibitor 
MolPort a: MolPort 009-737-181 [56] 
TLR2/1 & TLR2/6 inhibitor with a decr ase of cell viability 
 
 
ZINC: ZINC1676936 [56] 
NCI: Plated 2007: 44661TLR2/1 & TLR2/6 inhibitor 
MolPort a: MolPort 002-914-354 [56] 
TLR2/1 & TLR2/6 inhibitor 
  
ZINC: ZINC398557 [56] 
NCI: Plated 2007: 205636 
MolPort a: MolPort 0 -835-401 
TLR2/1 & TLR2/6 inhibitor 
C29 [127] 
TLR2 TIR domain inhibitor 
 
ZINC: ZINC1758666 [56] 
NCI: Plated 2007: 17379 
TLR2/1 & TLR2/6 inhibitor 
C29L (O-vanillin) [127] 
TLR2 TIR domain inhibitor 
ZINC: ZINC 85632 [56] TLR2/1 & TLR2/6 inhibitor 
MolPort a: l rt-001-796-266 [56]
TLR2/1 & 6 inhibitor
MolPort a: l t-009-737-181 [56]
TLR2/1 & TLR2/6 i i it r ith a decrease of cell viability
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hydrophobic contacts with Ile319, Phe322, Phe325, Val348, and Phe349 residues located deep inside the 
TLR2 pocket (Figure 2). 
A ligand-based strategy was followed using a shape- and feature-based similarity screening 
assisted by ROCS and using three reported small-molecule TLR2 signaling modulators (co pounds 
A & B, Figure 2) [31] and E567 (Figure 2) [126] against a NCI compound library of 260,071 compounds. 
Five hundred hits arose from the VS and, after visual inspection, 39 were selected for biological 
testing. Out of them, four exhibited antagonist activity (hit rate: 10%): compounds ZINC16769362 
and ZINC398557 (that were identified from compound B as query structure) and compounds 
ZINC1758666 and ZINC585632 (fr m E567 as query) (Table 2). 
Table 2. 2D Chemical structure of TLR2 modulators identified by VS techniques and mentioned in 
this review. The database codes are provided. a MolPort is a supplier of chemicals included in several 
VS databases (www.molport.com). 
TLR2/TLR1 TLR2/TLR6
  
3D structure from PDB-ID 2Z7X 3D structure from PDB-ID 3A79 
 
 
ZINC: ZINC12899676 [121] 
TLR2-TLR1 heterodimerization inhibitor 
ENA INE: Z416323354 [56] 
MolPort a: MolPort-009-315-475 
TLR2/1 & TLR2/6 inhibitor 
 
 
MolPort a: Molport-001-796-2 6 [56] 
TLR2/1 & TLR2/6 inhibitor 
MolPort a: MolPort-009-737-181 [56] 
TLR2/1 & TLR2/6 inhibitor with a decrease of cell viability 
 
 
ZINC: ZINC167 936 [56] 
NCI: Plated 2007: 44661TLR2/1 & TLR2/6 inhibitor 
MolPort a: MolPort-002-914-354 [56] 
TLR2/1 & TLR2/6 inhibitor 
  
ZINC ZINC398557 [56] 
NCI: Plated 2007: 2 5636 
MolPort a: MolPort-001-835-401 
TLR2/1 & TLR2/6 inhibitor 
C29 [127] 
TLR2 TIR domain inhibitor 
 
ZI : ZI 1758666 [56] 
NCI: Plated 2007: 17379
TLR2/1 & TLR2/6 inhibitor 
C29L (O-vanillin) [127] 
TLR2 TIR domain inhibitor 
ZINC: ZINC585632 [56] TLR2/1 & TLR2/6 inhibitor 
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hydrophobic contacts with Ile319, Phe32 , Phe325, Val348, and Phe349 residues located deep inside the 
TLR2 pocket (Figure 2). 
A ligan -based strategy was followed using a shape- nd feature-based simila ity screening 
assisted by ROCS a d using three reported small-molecule TLR2 si naling m dulators (compounds 
A & B, Figure 2) [31] and E567 (Figure 2) [126] against a NCI compound library of 260,071 compounds. 
Five hundred hits arose from the VS and, after visual inspection, 39 w re selected f r biological 
testing. Out of them, four xhibi ed antagonist activity (hit rate: 10%): compounds ZINC16769362 
and ZINC398557 (that w re dentified from compound B as query structure) and compounds 
ZINC1758666 and ZINC585632 (fro  E567 as query) (Table 2). 
Table 2. 2D Chemi al structure of TLR2 modulators i entified by VS techniques and mentioned in 
this revie . The databa e codes are provided. a MolPort is a suppli r of chemicals included in several 
VS databases (www.molport.com). 
TLR2/TLR1 TLR2/TLR6
  
3D structure from PDB-ID 2Z7X 3D structure from PDB-ID 3A79 
 
 
ZINC: ZINC12899676 [121] 
TLR2-TLR1 heterod merization inhibitor 
ENAMINE: Z416323354 [56] 
MolPort a: MolPor 009-315-475 
TLR2/1 & TLR2/6 inhibitor 
 
 
MolPort a: Molport 001-796-266 [56] 
TLR2/1 & TLR2/6 inhibitor 
MolP t a: M lPor 009-737-181 [56] 
TLR2/1 & TLR2/6 inhibitor with a decr ase of cell viability 
 
 
ZINC: ZINC167693  [56] 
NCI: Plated 2007: 44661TLR2/1 & TLR2/6 inhibitor 
MolPort a: MolPort 002-914-354 [56] 
TLR2/1 & TLR2/6 inhibitor 
  
ZINC: ZINC398557 [56]
NCI: la ed 2007: 205636 
MolPort a: MolPor 0 -835-401 
TLR2/1 & TLR2/6 inhibitor 
C29 [127] 
TLR2 TIR domain inhibitor 
 
ZINC: ZINC1 58666 [56] 
NCI: Plated 007: 17379 
TLR2/1 & TLR2/6 inhibitor 
C 9L (O-vanillin) [127] 
TLR2 TIR domain inhibitor 
ZINC: ZINC 85632 [56] TLR2/1 & TLR2/6 inhibitor 
ZINC: ZI 6936 [56]
NCI: Plated 2007: 44661TLR2 1 & TLR2/6 inhibitor
MolPort a: l rt-002-914-354 [56]
TLR2/1 & 2 6 inhibitor
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hydrophobic contacts with Ile319, Phe322, Phe325, Val348, and Phe349 residues located deep inside the 
TLR2 pocket (Figure 2). 
A ligand-based strategy was followed using a shape- and feature-based si ilarity screening 
assisted by ROCS and using three reported small-molecule TLR2 signaling modulators (co pounds 
A & B, Figure 2) [31] and E567 (Figure 2) [126] against a NCI compound library of 260,071 compounds. 
Five hundred hits arose from the VS and, after visual inspection, 39 were selected for biological 
testing. Out of them, four exhibited antagonist activity (hit rate: 10%): compounds ZINC16769362 
and ZINC398557 (that were identified from compound B as query structure) and compounds 
ZINC1758666 and ZINC585632 (from E567 as query) (Table 2). 
Table 2. 2D Che ical structure of TLR2 modulators identified by VS techniques and mentioned in 
this review. The database codes are provided. a MolPort is a supplier of chemicals included in several 
VS databases (www.molport.com). 
TLR2/TLR1 TLR2/TLR6
  
3D structure from PDB-ID 2Z7X 3D structure from PDB-ID 3A79 
 
 
ZINC: ZINC12899676 [121] 
TLR2-TLR1 heterodimerization inhibitor 
ENAMINE: Z416323354 [56] 
MolPort a: MolPort-009-315-475 
TLR2/1 & TLR2/6 inhibitor 
 
 
MolPort a: Molport-001-796-2 6 [56] 
TLR2/1 & TLR2/6 inhibitor 
MolPort a: MolPort-009-737-181 [56] 
TLR2/1 & TLR2/6 inhibitor with a decrease of cell viability 
 
 
ZINC: ZINC167 936 [56] 
NCI: Plated 2007: 44661TLR2/1 & TLR2/6 inhibitor 
MolPort a: MolPort-002-914-354 [56] 
TLR2/1 & TLR2/6 inhibitor 
  
ZINC: ZINC398557 [56] 
NCI: Plated 2007: 205636 
MolPort a: MolPort-001-835-401 
TLR2/1 & TLR2/6 inhibitor 
C29 [127] 
TLR2 TIR domain inhibitor 
 
ZINC: ZI 1758666 [56] 
NCI: Plated 2007: 17379 
TLR2/1 & TLR2/6 inhibitor 
C29L (O-vanillin) [127] 
TLR2 TIR domain inhibitor 
ZINC: ZINC585632 [56] TLR2/1 & TLR2/6 inhibitor 
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hydrophobic contacts with Ile319, Phe32 , Phe325, Val348, and Phe349 residues located deep inside the 
TLR2 pocket (Figure 2). 
A ligan -based strategy was followed using a shape- nd feature-based simila ity screening 
assisted by ROCS a d using three reported small-molecule TLR2 si naling m dulators (co pounds 
A & B, Figure 2) [31] and E567 (Figure 2) [126] against a NCI compound library of 260,071 compounds. 
Five hundred hits arose from the VS and, after visual inspection, 39 w re selected f r biological 
testing. Out of them, four xhibi ed antagonist activity (hit rate: 10%): compounds ZINC16769362 
and ZINC398557 (that were dentified from compound B as query structure) and compounds 
ZINC1758666 and ZINC585632 (from E567 as query) (Table 2). 
Table 2. 2D Chemi al structure of TLR2 modulators i entified by VS techniques and mentioned in 
this review. The databa e codes are provided. a MolPort is a suppli r of chemicals included in several 
VS databases (www.m lport.com). 
TLR2/TLR1 TLR2/TLR6
  
3D structure from PDB-ID 2Z7X 3D structure from PDB-ID 3A79 
 
 
ZINC: ZINC12899676 [121] 
TLR2-TLR1 heterod merization inhibitor 
ENAMINE: Z4 6323354 [56] 
MolPort a: MolPort 009-315-475 
TLR2/1 & TLR2/6 inhibitor 
 
 
MolPort a: Molport 001-796-266 [56] 
TLR2/1 & TLR2/6 inhibitor 
MolP rt a: MolPort 009-737-181 [56] 
TLR2/1 & TLR2/6 inhibitor with a decr ase of cell viability 
 
 
ZINC: ZINC1676936 [56] 
NCI: Plated 2007: 44661TLR2/1 & TLR2/6 inhibitor 
MolPort a: MolPort 002-914-354 [56] 
TLR2/1 & TLR2/6 inhibitor 
  
ZINC: ZINC398557 [56] 
NCI: Plated 2007: 205636 
MolPort a: MolPort 0 -835-401 
TLR2/1 & TLR2/6 inhibitor 
C29 [127] 
TLR2 TIR domain inhibitor 
 
ZINC: ZINC1 58666 [56] 
NCI: Plated 2007: 17379 
TLR2/1 & TLR2/6 inhibitor 
C29L (O-vanillin) [127] 
TLR2 TIR domain inhibitor 
ZINC: ZINC 85632 [56] TLR2/1 & TLR2/6 inhibitor 
ZINC: ZI 557 [5 ]
NCI: Plate : 205636
MolPort a: l rt-001-835-401
TLR2/1 & 2 6 inhibitor
C [ ]
TLR2 TIR ai inhibitor
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hydrophobic contacts with Ile319, Phe322, Phe325, Val348, and Phe349 residues located deep inside the 
TLR2 pocket (Figure 2). 
A ligand-based strategy was followed using a shape- and feature-based si ilarity screening 
assisted by ROCS and using three reported small-molecule TLR2 signaling modulators (co pounds 
A & B, Figure 2) [31] and E567 (Figure 2) [126] against a NCI compound library of 260,071 compounds. 
Five hundred hits arose from the VS and, after visual inspection, 39 were selected for biological 
testing. Out of them, four exhibited antagonist activity (hit rate: 10%): compounds ZINC16769362 
and ZINC398557 (that were identified from compound B as query structure) and compounds 
ZINC1758666 and ZINC585632 (from E567 as query) (Table 2). 
Table 2. 2D Chemical structure of TLR2 modulators identified by VS techniques and mentioned in 
this review. The database codes are provided. a MolPort is a supplier of chemicals included in several 
VS databases (www.molport.com). 
TLR2/TLR1 TLR2/TLR6
  
3D structure from PDB-ID 2Z7X 3D structure from PDB-ID 3A79 
 
 
ZINC: ZINC12899676 [121] 
TLR2-TLR1 heterodimerization inhibitor 
ENAMINE: Z4 6323354 [56] 
MolPort a: MolPort-009-315-475 
TLR2/1 & TLR2/6 inhibitor 
 
 
MolPort a: Molport-001-796-2 6 [56] 
TLR2/1 & TLR2/6 inhibitor 
MolPort a: MolPort-009-737-181 [56] 
TLR2/1 & TLR2/6 inhibitor with a decrease of cell viability 
 
 
ZINC: ZINC167 936 [56] 
NCI: Plated 2007: 44661TLR2/1 & TLR2/6 inhibitor 
MolPort a: MolPort-002-914-354 [56] 
TLR2/1 & TLR2/6 inhibitor 
  
ZINC ZINC398557 [56] 
NCI: Plated 2007: 20563
MolPort a: MolPort-001-835-401 
TLR2/1 & TLR2/6 inhibitor 
C29 [127] 
TLR2 TIR domain inhibitor 
 
ZINC: ZI 1758 66 [5 ]
NCI: Plated 2007: 17379 
TLR2/1 & TLR2/6 inhibitor 
C29L (O-vanillin) [127] 
TLR2 TIR domain inhibitor 
ZINC: ZINC585632 [56] TLR2/1 & TLR2/6 inhibitor 
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hydrophobic contacts with Ile319, Phe32 , Phe325, Val348, and Phe349 residues located deep inside the 
TLR2 pocket (Figure 2). 
A ligan -based strategy was followed using a shape- nd feature-based simila ity screening 
assisted by ROCS a d using three reported small-molecule TLR2 si naling m dulators (co pounds 
A & B, Figure 2) [31] and E567 (Figure 2) [126] against a NCI compound library of 260,071 compounds. 
Five hundred hits arose from the VS and, after visual inspection, 39 w re selected f r biological 
testing. Out of them, four xhibi ed antagonist activity (hit rate: 10%): compounds ZINC16769362 
and ZINC398557 (that were dentified from compound B as query structure) and compounds 
ZINC1758666 and ZINC585632 (from E567 as query) (Table 2). 
Table 2. 2D Chemi al structure of TLR2 modulators i entified by VS techniques and mentioned in 
this revie . The databa e codes are provided. a MolPort is a suppli r of chemicals included in several 
VS databases (www.m lport.com). 
TLR2/TLR1 TLR2/TLR6
  
3D structure from PDB-ID 2Z7X 3D structure from PDB-ID 3A79 
 
 
ZINC: ZINC12899676 [121] 
TLR2-TLR1 heterod merization inhibitor 
ENAMINE: Z4 6323354 [56] 
MolPort a: MolPort 009-315-475 
TLR2/1 & TLR2/6 inhibitor 
 
 
MolPort a: Molport 001-796-266 [56] 
TLR2/1 & TLR2/6 inhibitor 
MolP rt a: MolPort 009-737-181 [56] 
TLR2/1 & TLR2/6 inhibitor with a decr ase of cell viability 
 
 
ZINC: ZINC1676936 [56] 
NCI: Plated 2007: 44661TLR2/1 & TLR2/6 inhibitor 
MolPort a: MolPort 002-914-354 [56] 
TLR2/1 & TLR2/6 inhibitor 
  
ZINC ZINC398 57 [56] 
NCI: Plated 2007: 205636 
MolPort a: MolPort 0 -835-401 
TLR2/1 & TLR2/6 inhibitor 
C29 [127] 
TLR2 TIR domain inhibitor 
 
ZINC: ZINC1 58666 [56] 
NCI: Plated 2007: 17379 
TLR2/1 & TLR2/6 inhibitor 
C29L (O-vanillin) [127] 
TLR2 TIR domain inhibitor 
ZINC: ZINC 85632 [56] TLR2/1 & TLR2/6 inhibitor 
ZI : ZI 66 [ 6]
NCI: Plate : 17379
TLR2/1 & 2 6 inhibitor
C29L (O- i ) [127]
TLR2 TIR d i inhibitor
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hydrophob c contact  with Ile319, Phe322, Phe325, Val348, and Phe349 sidu s located deep nside the 
TLR2 pocket (Figure 2). 
A ligand-based str tegy was followed us g shape- and feat re-based similarity s reening 
assiste by ROCS nd using r e reported small-molecule TLR2 signaling modulators (c mpounds 
A & B, Figure 2) [31] and E567 (Figure 2) [126] ag nst a NCI compound library f 260,071 compounds. 
Five hundred hi s aros  f om the VS and, after vis al inspection, 39 were s lecte for bi logical 
testing. Out of them, four exhibited ant gonist activity hit rate: 10%): compounds ZINC16769362 
and ZINC398557 (that were identified from compound B as query structure) and compounds 
ZINC1758666 and ZINC585632 (from E567 as query) (Tabl  2). 
T ble 2. 2D Ch mical structure of TLR2 modulators identified by VS techniques and mentioned in 
this review. The database codes are provided. a MolPort is a supplier of chemicals included in several 
VS databases (www.molport.com). 
TLR2/TLR1 TLR2/TLR6
  
3D structure from PDB-ID 2Z7X 3D structure from PDB-ID 3A79 
 
 
ZINC: ZINC12899676 [121] 
TLR2-TLR1 heterodimerization inhibitor 
ENA INE: Z41632335  [ 6] 
MolPort a: MolPort-009-315-475 
TLR2/1 & TLR2/6 inhibitor 
 
 
MolPort a: Molport-001-796-266 [56]
TLR2/1 & TLR2/6 inhibitor 
MolPort a: MolPort-009-737-181 [56] 
TLR2/1 & TLR2/6 inhibitor with a decrease of cell viability 
 
 
ZINC: ZINC1676936 [56] 
NCI: Plated 2007: 44661TLR2/1 & TLR2/6 inhibitor 
MolPort a: MolPort-002-914-354 [56]
TLR2/1 & TLR2/6 inhibitor 
  
ZINC: ZINC398 57 [56]
NCI: lated 2007: 05636 
MolPort a: MolPort-001-835-401 
TLR2/1 & TLR2/6 inhibitor 
C29 [127] 
TLR2 TIR domain inhibitor 
 
ZINC: ZINC1758666 [56] 
NCI: Plated 2007: 17379 
TLR2/1 & TLR2/6 inhibitor 
C29  (O-van llin) [127] 
TLR2 TIR domain inhibitor 
ZINC: ZINC585632 [56] TLR2/1 & TLR2/6 inhibitor ZINC: ZINC585632 [56] TL 2 1 & TLR2/6 inhibitor
Mistry et al. [127] have also reported the identification of two novel small molecule inhibitors of
TLR2 signaling by targeting a pocket within the so-called BB loop of the TLR2 TIR domain (Figure 2).
The TIR domain, located on the cytosolic face of all TLRs and adaptor proteins [128] (in TLR2, MyD88
and TIRAP) has been proven to be key for signaling through the mediation of certain homotypic and
heterotypic PPIs [129] that triggers downstream signaling cascades and ends in the production of
pro-inflammatory cytokines and chemokines [130]. The crystal structures of human TLR2 and TLR1,
as well as the P681H mutant of the TLR2 TIR domain [131] revealed that the BB loop connects strand
β-B and helix α-B and sticks out of the structure. The P681H mutation in the BB loop has shown to
preclude the recruitment MyD88 and therefore TLR2 signaling.
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A pocket within this BB loop of hTLR2, formed by 10 residues (Tyr647, Cys673, Asp678, Phe679,
Ile680, Lys683, Asp687, Asp688, Asp691, and Ser692) neighboring the highly conserved Pro681 and
Gly682 pair, was selected as the target for searching new TLR2 modulators. Flexible ligand docking of
a collection of commercially available small molecules and FDA-approved compounds (>1 million
compounds) was performed using the DOCK algorithm [132] based on the anchor-and-grow search
method [133]. First, a primary docking was performed where each rotatable bond was minimized
while created without reminimizing the other bonds, with a minimization of the complete molecule
once it was built. The most favored conformation of each molecule in terms of interaction energy was
conserved. This resulted in the selection of 50,000 compounds that were subjected to a secondary
docking step with an additional simultaneous minimization step of all rotatable bonds against the
crystal structure (PDB-ID: 1FYW) and three additional conformations obtained from MD simulations
of the protein [134].
The top 1,000 compounds that exhibited the most favorable interaction energies, taking into
account every protein conformation, led to the selection of 149 compounds and 20 FDA-approved drugs
attending to chemical diversity and physicochemical properties for biological testing in HEK293T-TLR2
transfectants. Among them, compound C29 (Table 2) was able to disrupt both TLR2-TLR1 and
TLR2-TLR6 signaling induced by synthetic and bacterial agonist in human cell lines. Pam3CSK4- and
Pam2CSK4-induced IL-8 mRNA was decreased by compound C29 in stably transfected HEK-hTLR2 in
a dose dependent manner, as well as IL-1β gene expression in the human monocytic cell line THP-1.
Other effects were not exhibited in other TLR agonist- of TNF-α induced signaling nor cytotoxic effects.
This behavior was also observed when HEK-hTLR2 and THP-1 cells were stimulated with heat-killed
or live Gram-positive and Gram-negative bacteria.
Notwithstanding, C29 only showed activity on TLR2/1 signaling pathway, disrupting only
P3C-and Staphylococcus aureus lipoteichoic acid- induced IL-1β mRNA in murine macrophages. C29L
(O-vanillin), a derivative from the imine cleavage of C29 in alkaline conditions (NaOH, 65 µM),
displayed similar activity and potency in NF-κB luciferase reporter assay in HEK293T cells and has
the advantage of a better water solubility. It was shown to be active both in vitro and in vivo. In this
work, Mistry et al. also performed an Alanine scanning mutagenesis of every residue within the BB
loop using Y647A as a control mutation as it has been reported to play no role in TLR2 signaling [135].
All 10 BB loop pocket mutants resulted crucial for TRR2/1 signaling but not for TLR2/6 signaling,
were mutations C673A, I680A, K683A, and S692A were found to not be needed for TLR2/6 signaling.
4.2. Virtual Screening Studies in TLR3
Toll-like receptor 3 (TLR3) is located at the membrane of the endoplasmic reticulum, endosomes,
multivesicular bodies, and lysosomes. TLR3 forms a large horseshoe shape that contacts with a
neighboring horseshoe, yielding a dimer of two horseshoes. The overall horseshoe-shaped structure of
the TLR3 ectodomain is formed by 23 repeating LRRs, ligand-binding domain that is composed
of leucine-rich repeats (LRRs) [136]. Some X-ray crystallographic structures are available from
mouse (PDB-ID: 3CIG and 3CIY) and from human (PDB-ID: 2AOZ and 1ZIW). TLR3 recognizes
specifically dsRNA, and the activation of the receptor induces the secretion of type I interferons
and pro-inflammatory cytokines, like a TNF-α, IL-1 and IL-6, triggering immune cell activation and
recruitment of the adaptor molecule TRIF via TIR domain interaction [137]. In contrast to other
TLR ligands, dsRNA signaling occurs via MyD88-independent pathways [138]. It has also been
reported to recognize synthetic analogue polyinosinic-polycytidylic acid, Poly(I:C) [139]. Therefore, the
TLR3/dsRNA complex constitutes an important target in multiples infectious diseases and cancer, as
it has been shown to be implicated in several infection models like a herpes simplex encephalitis [140],
West Nile disease, phlebovirus, vaccinia and Influenza A [141–144]. It has also been reported that
double-stranded DNA from necrotic cells during inflammation or viral infection activates the signal of
TLR3 [145].
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Table 3. 2D Chemical structure of TLR3 and TLR7 modulators identified by VS techniques and
mentioned in this review. The database codes are provided.
TLR3 TLR7
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the advantage of a better water solubility. It was shown to be active both in vitro and in vivo. In this 
work, Mistry et al. also performed an Alanine scanning mutagenesis of every residue within the BB 
loop using Y647A as a control mutation as it has been reported to play no role in TLR2 signaling [135]. 
All 10 BB loop pocket mutants resulted crucial for TRR2/1 signaling but not for TLR2/6 signaling, 
were mutations C673A, I680A, K683A, and S692A were found to not be needed for TLR2/6 signaling. 
4.2. Virtual Screening Studies in TLR3 
Toll-like receptor 3 (TLR3) is located at the membrane of the endoplasmic reticulum, endosomes, 
multivesicular bodies, and lysosomes. TLR3 forms a large horseshoe shape that contacts with a 
neighboring horseshoe, yielding a dimer of two horseshoes. The overall horseshoe-shaped structure 
of the TLR3 ectodomain is formed by 23 repeating LRRs, ligand-binding domain that is composed of 
leucine-rich repeats (LRRs) [136]. Some X-ray crystallographic structures are available from mouse 
(PDB-ID: 3CIG and 3CIY) and from human (PDB-ID: 2AOZ and 1ZIW). TLR3 recognizes specifically 
dsRNA, and the activation of the receptor induces the secretion of type I interferons and pro-
inflammatory cytokines, like a TNF-α, IL-1 and IL-6, triggering immune cell activation and 
recruitment of the adaptor molecule TRIF via TIR domain interaction [137]. In contrast to other TLR 
ligands, dsRNA signaling occurs via MyD88-independent pathways [138]. It has also been reported 
to recognize synthetic analogue polyinosinic-polycytidylic acid, Poly(I:C) [139]. Therefore, the 
TLR3/dsRNA complex constitutes an important target in multiples infectious diseases and cancer, as 
it has been shown to be implicated in several infection models like a herpes simplex encephalitis 
[140], West Nile disease, phlebovirus, vaccinia and Influenza A [141–144]. It has also been reported 
that double-stranded DNA from necrotic cells during inflammation or viral infection activates the 
signal of TLR3 [145]. 
Cheng et al. have reported the development of small-molecule probes that exhibited activity as 
competitive inhibitors of dsRNA binding to TLR3 [146]. The authors performed a VS in the dsRNA 
binding domain of TLR3 using the ENAMINE drug database. The docking protocol was performed 
into the dsRNA binding domain of mouse TLR3 (PDB-ID: 3CIY) with Glide program. A HTVS 
protocol was employed for the first docking and ranking, followed by SP protocol for the top 10,000 
compounds. The resultant top 5000 compounds were subsequently docked using the more accurate 
and computationally intensive XP mode of Glide. First top-ranked 100 compounds were selected and 
re-ranked by predicted binding energy. The authors finally selected nine hits compounds for 
evaluation by cell assay of TLR3 activation (ENAMINE codes are: T5528092, T5631009, T5630975, 
T0519-9149, T5626448, T5643856, T5260630, T55994342, T0505-4844, Table 3). 
Table 3. 2D C emical structure of TLR3 an  TLR7 m dulators identified by VS techniques and 
mentioned in this review. The database codes are provided. 
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Most of these nine hits were found to share a structural motif: the chemical structure of a D-
amino acid conjugated with an aromatic substituent, thus yielding a new pharmacophore for the 
TLR3 binding site. To select the best ranked compounds, they took into account different benchmarks: 
(a) predicted binding energy and spatial complementarity; (b) reasonable chemical structures found 
in the dsRNA-binding site of TLR3; (c) existence of at least one H-bond between the ligand and one 
of the dsRNA-recognizing residues on the TLR3 surface (e.g., His539, Asn541, and Ser571); and (d) 
protonation state and tautomeric form of the ligand had to be acceptable. 
A dsRNA, Poly(I:C) was employed to selectively activate TLR3 signaling, resulting in the 
activation of nitric oxide (NO) synthase and the production of NO in RAW264.7 macrophage cells 
[147]. They monitored the NO level as an indicator of Poly(I:C)-induced TLR3 activation to evaluate 
the inhibitory activity. Hit compounds T5626448 and T5260630, both derivatives of D-Phe, were 
identified with IC50 values of 154 and 145 µM, respectively. Different analogues were synthesized 
and SAR analysis was performed. Finally, only one compound, a T5626448 derivative (compound 4a 
in Table 3), was identified as a very potent dose dependent TLR3 antagonist, with a low µM IC50 
value (3.44 ± 0.41 µM). However, in the case of T5260630 analogues, no significant improvement in 
the activity was observed, so they only focused on the T5626448 derivative family. 
Compound 4a was also tested against homologous TLRs: TLR1/2, TLR2/6, TLR3, TLR4 and TLR7 
using TLR specific ligands, but only TLR3 inhibition was observed. Other different biological assays 
were performed, finding that compound 4a did not affect cytochrome P450 CYP3A4, CYP2D6, and 
CYP2C19 isoforms. Tests on RAW264.7 macrophages were also carried out showing low toxicity, and 
kinase profiling showed that 4a demonstrates negligible inhibition activity against a panel of 12 
representative kinases. Biophysical tests were also carried out, with a negative control, to 
demonstrate that 4a binds to TLR3. Fluorescence anisotropy assay demonstrated that this compound 
competes with dsRNA for binding to TLR3 with a Ki value of 2.96 µM. By an ELISA assay, 4a was 
also demonstrated to inhibit the downstream signaling transduction mediated by the formation of 
the TLR3/ds RNA complex, showing that this compound almost completely abolishes the TLR3-
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(a) predicted binding energy and spatial complementarity; (b) reasonable chemical structures found 
in the dsRNA-binding site of TLR3; (c) existence of at least one H-bond betw en the ligand and one 
of the dsRNA-recognizing residues on the TLR3 surface (e.g., His539, Asn541, and Ser571); and (d) 
protonation state and tautomeric form of the ligand had to be acceptable. 
A dsRNA, Poly(I:C) was employed to selectively activate TLR3 signaling, resulting in the 
activation of nitric oxide (NO) synthase and the production of NO in RAW264.7 macrophage cells 
[147]. They monitored the NO level as an indicator of Poly(I:C)-induced TLR3 activation to evaluate 
the inhibitory activity. Hit compounds T5626 48 and T5260630, both derivatives of D-Phe, were 
ident fied with IC50 values of 154 and 145 µM, respectively. Different analogues were synthesized 
and SAR analy is was performed. Finally, only one compound, a T5626 48 derivative (compound 4a 
in Table 3), was ident fied as a very potent dose dependent TLR3 antagonist, with a low µM IC50 
value (3. 4 ± 0.41 µM). However, in the case of T5260630 analogues, no sign ficant improvement in 
the activity was observed, so they only focused on the T5626 48 derivative family. 
Compound 4a was also tested against homologous TLRs: TLR1/2, TLR2/6, TLR3, TLR4 and TLR7 
using TLR spec fic ligands, but only TLR3 inhib tion was observed. Other different biological assays 
were performed, finding that compound 4a did not affect cytochrome P450 CYP3A4, CYP2D6, and 
CYP2C19 isoforms. Tests on RAW264.7 macrophages were also carried out showing low toxicity, and 
kinase prof ling showed that 4a demonstrates negligible inhib tion activity against a panel of 12 
representative kinases. Biophysical tests were also carried out, with a negative control, to 
demonstrate that 4a binds to TLR3. Fluorescence anisotropy assay demonstrated tha  this compound 
competes with dsRNA for binding to TLR3 with a Ki value of 2.96 µM. By an ELISA assay, 4a was 
also demonstrated to inhibi  the downstream signaling transduction mediated by the formation of 
the TLR3/ds RNA complex, showing that this compound almost completely abolishes the TLR3-
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in the dsRNA-binding site of TLR3; (c) existence of a least one H-bond betwe n the ligand and one 
of the dsRNA-recog izing r idues on the TLR3 surface (e.g., His539, Asn541, and Ser571); and (d) 
prot ation st te nd tautome ic form of the ligand had to be acceptable. 
A dsRNA, Poly(I:C) was employed to selectively ac ivate TLR3 s g aling, resulting in the 
ac vatio  of nitric oxide (NO) synth se and the production of NO in RAW264.7 macrophage cells 
[147]. They m nitor d the NO level as an indicator f Poly(I:C)-in uced TLR3 ac vati n to evaluate 
t e nhibitory activity. Hit compounds T5626448 and T5260630, both der atives of D-Phe, were 
d ntified with IC50 values of 154 and 145 µM, respectively. Differe t analogues were synth sized 
and SAR analysis was performed. Finall , ly ne compound, a T5626448 der ative (compound 4a 
in Table 3), was d ntified as a very potent ose dep dent TLR3 antagonist, with a low µM IC50 
value (3.4  ± 0.41 µM). However, in th  case of T5260630 analogue , no sig ificant improvement in 
the activity wa  observed, so the only focused on the T5626448 der ative family. 
Compound 4a was also tested against h mologous TLRs: TLR1/2, TLR2/6, TLR3, TLR4 and TLR7 
using TLR specific ligands, but only TLR3 nhibition wa  observed. Other different b ologic l assays 
w e performe , finding that compoun  4a did not affec  cytochrome P450 CYP3A4, CYP2D6, and 
YP2C19 isoforms. Tests on RAW264.7 macrophages were lso carried out showing low toxicity, and 
kinase profiling showed th t 4a demonstrates negligible nhibition activity against a panel of 12 
r presentative kinases. Biophysical tests were also carried ou , with a negative c ntrol, to 
demons r te th t 4a binds to TLR3. Fluoresce ce anisotropy assay demonstra ed that this compound 
competes with dsRNA for binding to TLR3 with a Ki value of 2.96 µM. By an ELISA assay, 4  was 
also demonstra ed to nhibit the downstream s g aling transduction m iated by the formation of 
the TLR3/ds RNA complex, showing t at this compound alm st completely abolis s the TLR3-
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Most of these nine hits were found to share a structural motif: the chemical structure of a D-
amino acid conjugated with an aromatic substituent, thus yielding a new pharmacophore for the 
TLR3 binding site. To select the best ranked compounds, they took into account different benchmarks: 
(a) predicted binding energy and spatial complementarity; (b) reasonable chemical structures found 
in the dsRNA-binding site of TLR3; (c) existence of at least one H-bond between the ligand and one 
of the dsRNA-recognizing residues on the TLR3 surface (e.g., His539, Asn541, and Ser571); and (d) 
protonation state and tautomeric form of the ligand had to be acceptable. 
A dsRNA, Poly(I:C) was employed to selectively activate TLR3 signaling, resulting in the 
activation of nitric oxide (NO) synthase and the production of NO in RAW264.7 macrophage cells 
[147]. They monitored the NO level as an indicator of Poly(I:C)-induced TLR3 activation to evaluate 
the inhibitory activity. Hit compounds T5626448 and T5260630, both derivatives of D-Phe, were 
identified with IC50 values of 154 and 145 µM, respectively. Different analogues were synthesized 
and SAR analysis was performed. Finally, only one compound, a T5626448 derivative (compound 4a 
in Table 3), was identified as a very potent dose dependent TLR3 antagonist, with a low µM IC50 
value (3.44 ± 0.41 µM). However, in the case of T5260630 analogues, no significant improvement in 
the activity was observed, so they only focused on the T5626448 derivative family. 
Compound 4a was also tested against homologous TLRs: TLR1/2, TLR2/6, TLR3, TLR4 and TLR7 
using TLR specific ligands, but only TLR3 inhibition was observed. Other different biological assays 
were performed, finding that compound 4a did not affect cytochrome P450 CYP3A4, CYP2D6, and 
CYP2C19 isoforms. Tests on RAW264.7 macrophages were also carried out showing low toxicity, and 
kinase profiling showed that 4a demonstrates negligible inhibition activity against a panel of 12 
representative kinases. Biophysical tests were also carried out, with a negative control, to 
demonstrate that 4a binds to TLR3. Fluorescence anisotropy assay demonstrated that this compound 
competes with dsRNA for binding to TLR3 with a Ki value of 2.96 µM. By an ELISA assay, 4a was 
also demonstrated to inhibit the downstream signaling transduction mediated by the formation of 
the TLR3/ds RNA complex, showing that this compound almost completely abolishes the TLR3-
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(a) predicted binding energy and spatial complementarity; (b) reasonable chemical structures found 
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protonation state and tautomeric form of the ligand had to be a ceptable. 
A dsRNA, Poly(I:C) was employed to selectively activate TLR3 signaling, resulting in the 
activation of nitric oxide (NO) synthase and the production of NO in RAW264.7 macrophage cells 
[147]. They monitored the NO level as an indicator of Poly(I:C)-induced TLR3 activation to evaluate 
the inhibitory activity. Hit compounds T5626 48 and T5260630, both derivatives of D-Phe, were 
ident fied with IC50 values of 154 and 145 µM, respectively. Different analogues were synthesized 
and SAR analy is was performed. Finally, only one compound, a T5626 48 derivative (compound 4a 
in Table 3), was ident fied as a very potent dose dependent TLR3 antagonist, with a low µM IC50 
value (3. 4 ± 0.41 µM). However, in the case of T5260630 analogues, no sign ficant improvement in 
the activity was observed, so they only focused on the T5626 48 derivative family. 
Compound 4a was also tested against homologous TLRs: TLR1/2, TLR2/6, TLR3, TLR4 and TLR7 
using TLR spec fic ligands, but only TLR3 inhib tion was observed. Other different biological assays 
were performed, finding that compound 4a did not affect cytochrome P450 CYP3A4, CYP2D6, and 
CYP2C19 isoforms. Tests on RAW264.7 macrophages were also carried out showing low toxicity, and 
kinase prof ling showed that 4a demonstrates negligible inhib tion activity against a panel of 12 
representative kinases. Biophysical tests were also carried out, with a negative control, to 
demonstrate that 4a binds to TLR3. Fluorescence anisotropy assay demonstrated tha  this compound 
competes with dsRNA for binding to TLR3 with a Ki value of 2.96 µM. By an ELISA assay, 4a was 
also demonstrated to inhibi  the downstream signaling transduction mediated by the formation of 
the TLR3/ds RNA complex, showing that this compound almost completely abolishes the TLR3-
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d ntified with IC50 values of 154 and 145 µM, respectively. Differe t analogues were synth sized 
and SAR analysis was performed. Finall , ly ne compound, a T5626448 der ative (compound 4a 
in Table 3), was d ntified as a very potent ose dep dent TLR3 antagonist, with a low µM IC50 
value (3.4  ± 0.41 µM). However, in th  case of T5260630 analogue , no sig ificant improvement in 
the activity wa  observed, so the only focused on the T5626448 der ative family. 
Compound 4  was also tested against h mologous TLRs: TLR1/2, TLR2/6, TLR3, TLR4 and TLR7 
using TLR specific ligands, but only TLR3 nhibition wa  observed. Other different b ologic l assays 
w e performe , finding that compoun  4a did not affec  cytochrome P450 CYP3A4, CYP2D6, and 
YP2C19 isoforms. Tests on RAW264.7 macrophages were lso carried out showing low toxicity, and 
kinase profiling showed th t 4a demonstrates negligible nhibition activity against a panel of 12 
r presentative kinases. Biophysical tests were also carried ou , with a negative c ntrol, to 
demons r te th t 4a binds to TLR3. Fluoresce ce anisotropy assay demonstra ed that this compound 
competes with dsRNA for binding to TLR3 with a Ki value of 2.96 µM. By an ELISA assay, 4  was 
also demonstra ed to nhibit the downstream s g aling transduction m iated by the formation of 
the TLR3/ds RNA complex, showing t at this compound alm st completely abolis s the TLR3-
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(a) predicted bi di g e ergy nd spatial complementarity; (b) r asonabl  chemi al ructures found 
in the dsRNA-binding site of TLR3; (c) existenc  of at least one H-bond b twee the liga d and one 
of the dsRNA-recog izing residu s on the TLR3 surface (e.g., Hi 39, Asn541, and Ser571); and (d) 
proton tion st te and tauto eric form of the ligand had to be acceptable. 
dsRNA, Poly(I:C) was mploy d o sele ely ac ivate TLR3 sig aling, resulting in the 
ac vation f nitric oxide (NO) synth se and the production of NO in RAW264.7 macrophage cells 
[147]. They m nitored th  NO level as an indicator f Poly(I:C)-induced TLR3 ac vati n o valuate 
the inhibitory activity. Hit compounds T5626448 and T5260630, both d r atives of D-Phe, were 
i entified with IC50 values of 5  and 145 µM, respectively. Differe t analogue  wer  synth sized 
d SAR analysis was performed. Fi ally, only one compound, a T5626448 d r ative (compound 4a 
in Table 3), was i entified as a v ry p t nt dose dep dent TLR3 antagonist, ith a low µM IC50 
value (3.44 ± 0.41 µM). Howev r, in the case of T5260630 analogues, no significant i provement in 
he activity wa  ob erved, so they only f cused on the T5626448 d r at ve family. 
Compound 4 wa  also tested against h mologous TLRs: TLR1/2, TLR2/6, TLR3, TLR4 and TLR7 
using TLR specific ligands, but only TLR3 i hibiti n wa  observ . Other d fferent biological assays 
were performed, finding that compound 4a did not affec  cytochrome 450 CYP3A4, CYP2D6, and 
CYP2C19 isoforms. Tests on RAW264.7 macrophages we e als carried out sh ing low toxicity, and 
kinase profiling s owed th t 4a demo strates n glig le i hibit on act vity ag inst a panel of 12 
repr sentativ  kinases. Biophy ical t sts were also carried out, with a nega ive c ntrol, to 
demonstr te th t 4a binds to TLR3. Fluorescence anisotropy assay demonstra ed that this compound 
competes with dsRNA for binding to TLR3 with a Ki value of 2.96 µM. By an ELISA ssay, 4  was 
also demonstra ed to inhibit the down tream sig ling ra sduction mediated by the formation of 
the TLR3/ds RNA complex, s owing that this compound al os  completely abolishes the TLR3-
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Most of these nine hits were found to share a structural motif: the che ical structure of a D-
amino acid conjugated with an aromatic substituent, thus yielding a new pharmacophore for the 
TLR3 binding site. To select the best ranked compounds, they took into account different benchmarks: 
(a) predicted binding energy and spatial complementarity; (b) reasonable chemical structures found 
in the dsRNA-binding site of TLR3; (c) existence of at least one H-bond between the ligand and one 
of the dsRNA-recognizing residues on the TLR3 surface (e.g., His539, Asn541, and Ser571); and (d) 
protonation state and tautomeric form of the ligand had to be acceptable. 
A dsRNA, Poly(I:C) was employed to selectively activate TLR3 signaling, resulting in the 
activation of nitric oxide (NO) synthase and the production of NO in RAW264.7 macrophage cells 
[147]. They monitored the NO level as an indicator of Poly(I:C)-induced TLR3 activation to evaluate 
the inhibitory activity. Hit compounds T5626448 and T5260630, both derivatives of D-Phe, were 
identified with IC50 values of 154 and 145 µM, respectively. Different analogues were synthesized 
and SAR analysis was performed. Finally, only one compound, a T5626448 derivative (compound 4a 
in Table 3), was identified as a very potent dose dependent TLR3 antagonist, with a low µM IC50 
value (3.44 ± 0.41 µM). However, in the case of T5260630 analogues, no significant improvement in 
the activity was observed, so they only focused on the T5626448 derivative fa ily. 
Compound 4a was also tested against ho ologous TLRs: TLR1/2, TLR2/6, TLR3, TLR4 and TLR7 
using TLR specific ligands, but only TLR3 inhibition was observed. Other different biological assays 
were performed, finding that compound 4a did not affect cytochrome P450 CYP3A4, CYP2D6, and 
CYP2C19 isoforms. Tests on RAW264.7 macrophages were also carried out showing low toxicity, and 
kinase profiling showed that 4a demonstrates negligible inhibition activity against a panel of 12 
representative kinases. Biophysical tests were also carried out, with a negative control, to 
demonstrate that 4a binds to TLR3. Fluorescence anisotropy assay demonstrated that this compound 
competes with dsRNA for binding to TLR3 with a Ki value of 2.96 µM. By an ELISA assay, 4a was 
also demonstrated to inhibit the downstream signaling transduction mediated by the formation of 
the TLR3/ds RNA complex, showing that this compound almost completely abolishes the TLR3-
mediated inflammation response at its IC90 concentration (27 µM). Finally, the inhibitory effects of 
TNF-α by compound 4a at 10 µM were also tested with a result of 60% inhibition, agreeing with the 
results observed in the NO synthase assay. 
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Most of these nine hits were found to share a structural motif: the che ical structure of a D-
amino acid conjugated with an aromatic subs ituent, thus yielding a ne  pharmacophore for the 
TLR3 binding site. To selec  the best ranked compounds, they t ok into account different benchmarks: 
(a) predicted binding energy and spatial complementarity; (b) reasonable chemical structures found 
in the dsR -binding site of TLR3; (c) existence of at least one H-bond betw en the ligand and one 
of the dsRNA-recognizing residues on the TLR3 surface (e.g., His539, sn541, and Ser571); and (d) 
protonation state and tautomeric form of the ligand had to be acceptable. 
A dsRNA, Poly(I:C) was employed to selectively activate TLR3 signaling, resulting in the 
activation of nitric oxide (NO) synthase and the production of NO in RAW264.7 macrophage cells 
[147]. They monitored the NO level as an indicator of Poly(I:C)-induced TLR3 activation to evaluate 
the inhibitory activity. Hit compounds T5626 48 and T5260630, both derivatives of D-Phe, were 
ident fied with IC50 values of 154 and 145 µM, respectively. Different analogues were synthesized 
and SAR analy is was performed. Finally, only one compound, a T5626 48 derivative (compound 4a 
in Table 3), was ident fied as a very potent dose dependent TL 3 antagonist, with a low µM IC50 
value (3. 4 ± 0.41 µM). However, in the case of T5260630 analogues, no sign ficant improvement in 
the activity was observed, so they only focused on the T5626 48 derivative family. 
Compound 4a was also tested against homologous TLRs: TLR1/2, TLR2/6, TLR3, TLR4 and TLR7 
using TLR spec fic ligands, but only TLR3 inhib tion was observed. Other different biological assays 
were performed, finding that compound 4a did not affect cytochrome P450 CYP3A4, CYP2D6, and 
CYP2C19 isoforms. Tests on RAW264.7 macrophages were also carried out showing low toxicity, and 
kinase prof ling showed that 4a demonstrates negligible inhib tion activity against a panel of 12 
representative kinases. Biophysical tests were also carried out, with a negative control, to 
demonstrate that 4a binds to TLR3. Fluorescence anisotropy assay de onstrated tha  this compound 
competes with dsRNA for binding to TLR3 with a Ki value of 2.96 µM. By an ELISA assay, 4a was 
also demonstrated to inhibi  the downstream signaling transduction mediated by the formation of 
the TLR3/ds RNA complex, showing that this compound almost completely abolishes the TLR3-
mediated infla mation response at its IC90 concentration (27 µM). Finally, the inhibitory effects of 
TNF-α by compound 4  at 10 µM were also tested with a result of 60% inhib tion, agr eing with the 
results observed in the NO synthase assay. 
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M st of thes n ne hits were found to sh re a s uctural motif: t  che ical s ucture of a D-
amino a id conjugated with an romatic ubstituent, thus y eldi g a new ph rmac phore for the 
TLR3 binding site. To sel ct the best ranked compounds, they took int  account differ t benchmarks: 
(a) pr icte  bindi g energy and spatial co plementarity; (b) reasonabl  chemical s uctures found 
in the dsRNA-binding site of TLR3; (c) existence of a least one H-bond betwe n the ligand and one 
of the dsRNA-recog izing r idues on the TLR3 surface (e.g., His539, Asn541, and Ser571); and (d) 
prot ation st te nd tautome ic form of the ligand had to be acceptable. 
A dsRNA, Poly(I:C) was employed to selectively ac ivate TLR3 s g aling, resulting in the 
ac vation of nitric oxide (NO) synth se and the production of NO in RAW264.7 macrophage cells 
[147]. They m nitor d the NO level as an indicator f Poly(I:C)-in uced TLR3 ac vati n to evaluate 
t e nhibitory activity. Hit compounds T5626448 and T5260630, both der atives of D-Phe, were 
d ntified with IC50 values of 154 and 145 µM, respectively. Differe t analogues were synth sized 
and SAR analysis was performed. Finall , ly ne compound, a T5626448 der ative (compound 4a 
in Table 3), was d ntified as a very potent ose dep dent TL 3 antagonist, with a low µM IC50 
value (3.4  ± 0.41 µM). However, in the case of T5260630 analogue , no sig ificant improvement in 
the activity wa  observed, so the only focused on the T5626448 der ative family. 
Compound 4a was also tested against h mologous TLRs: TLR1/2, TLR2/6, TLR3, TLR4 and TLR7 
using TLR specific ligands, but only TLR3 nhibition wa  observed. Other different b ologic l assays 
w e performe , finding that compoun  4a did not affec  cytochrome P450 CYP3A4, CYP2D6, and 
YP2C19 isoforms. Tests on AW264.7 macrophages were lso carried out showing low toxicity, and 
kinase profiling showed th t 4a demonstrates negligible nhibition activity against a panel of 12 
r presentative kinases. Biophysical tests were also carried ou , with a negative c ntrol, to 
demons r te th t 4a binds to TLR3. Fluoresce ce anisotropy assay demonstra ed that this compound 
competes with dsRNA for binding to TLR3 with a Ki value of 2.96 µM. By an ELISA assay, 4  was 
also demonstra ed to nhibit the downstream s g aling transduction m iated by the formation of 
the TLR3/ds RNA complex, showing t at this compound alm st completely abolis s the TLR3-
m iated infl mmation response at its IC90 oncentration (27 µM). Finally, t e nhibitory effects of 
TNF-α by compound 4a at 10 µM were also tested with a result of 60% nhibition, agreeing with the 
re ult  observed in the NO synth e assay. 
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M st of these nine hits were found to sh re a s ruc ural motif: t e che i al s ructure of a D-
amin  a id conjugated with an aroma c ubstit ent, thus y elding a new ph rmac phor for the 
TLR3 binding it . To select the b st ranked compounds, they took into accou different benchmarks: 
(a) predicted bi di g e ergy nd spatial complementarity; (b) r asonabl  chemi al ructures found 
in the dsRNA-binding site of TLR3; (c) xistenc  of at least one H-bond b twee the liga d and one 
of the dsRNA-recog izing residu s on the TLR3 surface (e.g., Hi 39, Asn541, and Ser571); and (d) 
proton tion st te and tauto eric form of the ligand had to be acceptable. 
dsRNA, Poly(I:C) was mploy d o sele ely ac ivate TLR3 sig aling, resulting in the 
ac vation f nitric oxide (NO) synth se an the production of NO in RAW264.7 macrophage cells 
[147]. They m nitored th  NO level as an indicator f Poly(I:C)-induced TLR3 ac vati n o valuate 
the inhibitory activity. Hit compounds T5626448 and T5260630, both d r atives of D-Phe, were 
i entified with IC50 values of 5  and 145 µM, respectively. Differe t analogue  wer  synth sized 
d SAR an lysis was performed. Fi ally, only one compound, a T5626448 d r ative (compound 4a 
in Table 3), as i entifi d as a v ry p t nt dose dep dent TLR3 antagonist, ith a low µM IC50 
value (3.44 ± 0 41 µM). Howev r, in the case of T5260630 analogues, no significant i proveme t in 
he activity wa  ob erved, so they only f cused on the T5626448 d r at ve family. 
Co pound 4 wa  also tested against h mologous TLRs: TLR1/2, TLR2/6, TLR3, TLR4 and TLR7 
using TLR specific ligands, but only TLR3 i hibiti n wa  observ . Other d fferent biological assays 
were performed, finding that compound 4a did not affec  cytochrome P450 CYP3A4, CYP2D6, and 
CYP2C19 isoforms. Tests on RAW264.7 macrophages we e als carried out sh ing low toxicity, and 
kinase profiling showed th t 4a demo strates n glig le i hibit on act vity ag inst a panel of 12 
repr sentativ  kinases. Biophy ical t sts were also carried out, with a nega ive c ntrol, to 
demonstr te th t 4a binds to TLR3. Fluorescence ani otropy assay demonstra ed that this compound 
competes with dsRNA for binding to TLR3 with a Ki value of 2.96 µM. By an ELISA ssay, 4  was 
also demonstra ed to inhibit the down tre m sig ling ra sduction mediated by the formation of 
the TLR3/ds RNA complex, s owing that this compound al os  completely abolishes the TLR3-
mediated inflammati  response at its IC90 o centration (27 µM). Finally, the inhibitory effects of 
TNF-α by compound 4a at 10 µM w re also ested with a result of 60% i hibitio , agreeing with the 
re ult  observ d in the NO synth e assay. 
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Most of these nine hits ere found to s are a structural motif: the chemical structure of a D-
amino acid conjugated with an aromatic substituent, thus yielding a new pharmacophore for the 
TLR3 binding sit . To l c  he b st ra ked c mpounds, they took into acc unt different benchm rks: 
(a) predicte b ding er y d spati l complem ari y; (b) r ason bl  chemical st uctu s found
in the dsR - of TLR3; (c) exi ence f at least o e -bond between th  ligand and one 
of the sRNA-r cog iz residues on the TLR3 surf c  (e.g., His539, Asn541, and S 571); and (d)
proto a ion state and tautomeric orm of the ligand had to b  acceptable.
A , Poly(I:C) was employed to s lectively activ t TLR3 signaling, resulting in the
activati n f ni ric oxide ( ) synthase and the produc ion of NO in RAW264.7 macrophage cells 
[147]. They monitored the NO level as an indica r of Poly(I:C)-induc d TLR3 ctivation to eval a
the nhibit ry activ y. H t compounds T5626448 an  T5260630, both derivatives of D-P e, wer
identified with IC50 valu s of 154 and 145 µM, respectively. D fferent analogues were synthesized
and SAR analysis s performed. Fi ally, only one compound, a 26448 derivative (compound 4a
n Tabl  3), as identified as  v ry potent dose de nd nt TLR3 ant gonist, with a low µM IC50
v lue (3.44 ± 0.41 µM). Ho ver, in the case of T5260630 a al gues, no signif c nt impr vement in
the ctivity as observed, so they only f cused n th  T5626448 deriv tive family. 
Compo nd 4a was als tested against om logous TLRs: TLR1/2, TLR2/6 TLR3, TLR4 and TLR7
using TLR spec fic ligan s, but only TLR3 inhibition was observe . Other di ferent biological assays 
were performe , fi i g that comp und 4a did n t affect cytochrome P450 CYP3A4, CYP2D6, and
CYP2C19 i oforms. Tests on RAW264.7 macrophages ere also c rried out s owi g low t x ity, and
kinas r filing show t t 4a demo strates egligible inhibiti n activity against a panel of 12
representat ve kinas . Biophysical tests were als  c rried out, w th a ne ative c ntrol, o
de onst ate that 4a bi s to TLR3. Flu re ce ce isotropy assay demons ra ed hat th s com und
comp t s with dsRNA for bind ng t  TLR3 i h a Ki v lue of 2.96 µM. By n ELISA assay, 4a was
also e strated to inhibit the downstr am ig al ng transduction ediate  by he formati n of
the TLR3/ds RNA complex, showing that this compound almost completely abolishes the TLR3-
medi ted inflam ati r sp nse at its IC90 co centration (27 µM). Finally, h inh bitory ffects
TNF-α by compound 4a at 10 µM ere also te ed with a result f 60% inhibition, agre ing wit  the 
results obs rved in he NO sy thase a say. 
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Most of these ni e hits were fou d to share a structural motif: the c emical structure of a D-
amino acid conjugated with an aromatic subs ituent, thus yielding a new pharmacophore for the 
TLR3 binding site. To s lec  t  b st a k d compounds, hey ok int a oun  different benchm rks: 
(a) pred ted bindi g en rgy d spatial co plem ar y; (b) reason bl  ch mical structu s found
in the dsR A-binding site of TLR3; (c) exist ce f at least on  H-b nd betw en he liga d a d o e 
of the sRNA-reco nizing r si ues on the TLR3 surf ce ( .g., His539, Asn541, nd Ser571); and (d)
protonation state a d taut m ric for  of th  liga d had o b a ceptable. 
A dsRNA, Poly(I:C) was mployed t  selectively activate TLR3 signali g resulting in the
ac ivation of i ric oxid ( O) synthase and t  pro uc ion f NO in RAW264 7 macrophage cells 
[147]. They monitored the NO leve   an indicator f Poly(I:C)-induced TLR3 act vatio  o evaluat
the inhibi ry a tivity. Hit compound T5626 48 and T5260630, both der vatives of D-Ph , w re
ident fi d with IC50 valu s of 154 nd 145 µM, espe tively. Differe t analogues were synthesiz d
and SAR analysis was perfor ed. Fi ally, only one compound, a T5 2 48 der ative (comp und 4a
n Tabl 3), was ident fied as a very potent ose dependent TLR3 ant gonist, with a low µM IC50
value (3. 4 ± 0.41 µM). H wev r,  the c se of T5260630 a alogues, no sign f c nt i prove ent i
the activity as observ , so hey only focus d on th  T5626 48 riv ive f mily. 
Compound 4a was also tested agai st h mologous LRs: TLR1/2, TLR2/6, TLR3, TLR4 and TLR7
using TLR spec fic lig n , but nly TLR3 i hib tion was observ d. O her d fferent biological assays 
were perf r e , finding th t compound 4a d d n t affect cytochrome P450 CYP A4, CYP2D6, and
CYP2C19 soforms. T st  o  RAW264.7 macrophages ere ls  car i  ou  showi g l w toxicity, and
kinas  pr f ling showed t t 4  de onstrates negligible inhib i n a tivity against a panel of 1
representative kinas . Biophysical tests we e also c rri d ut, with a e ative control, to
de o st ate that 4a bin  t TLR3. Flu resc nce an sotropy assay dem s rated tha  thi  comp und
competes wi h dsRNA for bind ng to TLR3 ith a Ki v lue of 2.96 µM. By ELISA ssay, 4a was
als  demonstra ed to inh bi  the d wnstream sig aling tran duction ediate  by  for ati  f
the TLR3/ds RNA complex, sh wing that this compound almost completely bolishes the TLR3-
me iated i fla mat o  respo se at its IC90 conce tration (27 µM). Finally, he inhi it  eff cts
TNF-α by compound 4a at 10 µM were lso te ted with a result f 60% inhib tion, agr ng with the 
r sul s obs rved in the NO sy th e a ay.
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Most of thes n ne hits were f u d t  sha e a st uctural motif: t e c emical st ucture of a D-
amino acid conjuga ed with an romatic substi uent, thus yieldi g a new pharmacoph re for the 
TLR3 binding si . To sel ct th best ranke  co po nds, hey ook int  ac ount differ t benchmarks: 
( ) pr cte  bin in  energy nd spatial co plementarity; (b) reasonable chemical st uct res found 
in the d RNA-binding sit  of TLR3; ( ) xiste ce of a least one H-bo d betw n the liga d a d one 
of the sRNA-r co nizi r i ues on he TLR3 surface ( .g., His539, Asn541, nd Ser571); and (d) 
prot ation state taut e i  form of the ligand had to b cc ptabl . 
A dsRNA, Poly(I:C) was empl yed to s ctively ctivate TLR3 s ali g, resulting in the 
c iva ion of i ric xi  (NO) yn ase  the pr uction of NO in RAW264.7 macrophage cells 
[147]. They monitor d th  NO leve as an ind cat r of Poly(I:C)-in uced TLR3 ct vation to evaluate 
t e nhib ory a tivity. Hit compou ds T5626448 a d T5260630, both deriv tives of D-Ph , wer  
d ntifi d with IC50 valu s of 154  145 µM, respectively. Different analogu s wer  yn h siz d 
and SAR analy is was perfor e . Fina ly, ly ne compound, a T5626448  (c mpound 4a 
n Table 3), was d ntified as a very potent ose pendent TLR3 antago ist, with a low µM IC50 
value (3 ± 0.41 µM). H wever, th  case of T5260630 nalogue , o sig ficant improvement in 
th activity was observ , s  the ly f cuse  o  th  T5626448 deriv tive fam ly. 
Compound 4a was also tested gainst h mologous s: TLR1/ , TLR2/6 3, TLR4 and TLR7 
using TLR sp cific ligand , but onl  TLR3 nhibiti  was obs r d. O h r different b ologic l assays 
w e perf rme , finding that co poun  4a did n t affe t cytochrome P450 CYP A4, CYP2D6, and 
YP2C19 isoform . Test   RAW264.7 acr p g s were lso car ie  ut showin  l w toxicity, nd 
kinas  pro li g showed that 4a dem nstra es negl gible nhibition activity against a p el of 12 
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top 10,000 comp u s. Th r sultant top 5000 c mp unds were sub eque tly d ck d using the more
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selected and re-ranked by predicted binding energy. The authors finally selected nine hits compounds
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acid onjug ted i h an aromatic substi ue , thus yielding new ph rmacophore f r the TLR3
binding site. l t th b t ra ked c mp nds, they t k into ac unt differ nt benchm rks:
(a) predicted bindi g ener y nd spa i l c mplem ntari y; (b) reasonable che ical structures found
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in the dsRNA-binding site of TLR3; (c) existence of at least one H-bond between the ligand and
one of the dsRNA-recognizing residues on the TLR3 surface (e.g., His539, Asn541, and Ser571); and
(d) protonation state and tautomeric form of the ligand had to be acceptable.
A dsRNA, Poly(I:C) was employed to selectively activate TLR3 signaling, resulting in the
activation of nitric oxide (NO) synthase and the production of NO in RAW264.7 macrophage cells [147].
They monitored the NO level as an indicator of Poly(I:C)-induced TLR3 activation to evaluate the
inhibitory activity. Hit compounds T5626448 and T5260630, both derivatives of D-Phe, were identified
with IC50 values of 154 and 145 µM, respectively. Different analogues were synthesized and SAR
analysis was performed. Finally, only one compound, a T5626448 derivative (compound 4a in
Table 3), was identified as a very potent dose dependent TLR3 antagonist, with a low µM IC50
value (3.44 ± 0.41 µM). However, in the case of T5260630 analogues, no significant improvement in
the activity was observed, so they only focused on the T5626448 derivative family.
Compound 4a was also tested against homologous TLRs: TLR1/2, TLR2/6, TLR3, TLR4 and TLR7
using TLR specific ligands, but only TLR3 inhibition was observed. Other different biological assays
were performed, finding that compound 4a did not affect cytochrome P450 CYP3A4, CYP2D6, and
CYP2C19 isoforms. Tests on RAW264.7 macrophages were also carried out showing low toxicity,
and kinase profiling showed that 4a demonstrates negligible inhibition activity against a panel
of 12 representative kinases. Biophysical tests were also carried out, with a negative control, to
demonstrate that 4a binds to TLR3. Fluorescence anisotropy assay demonstrated that this compound
competes with dsRNA for binding to TLR3 with a Ki value of 2.96 µM. By an ELISA assay, 4a was
also demonstrated to inhibit the downstream signaling transduction mediated by the formation of the
TLR3/ds RNA complex, showing that this compound almost completely abolishes the TLR3-mediated
inflammation response at its IC90 concentration (27 µM). Finally, the inhibitory effects of TNF-α by
compound 4a at 10 µM were also tested with a result of 60% inhibition, agreeing with the results
observed in the NO synthase assay.
4.3. Virtual Screening Studies in TLR4
Toll-like receptor 4 (TLR4) plays a key physiologic role in host response to Gram-negative
bacterial infection [148,149]. An excessively potent and/or prolonged TLR4 response can lead to
life-threatening pathology, such as septic shock, inflammation and can also be associated with
autoimmune diseases [149]. TLR4 is a trans-membrane protein, being the ectodomain widely
studied and believed to be primarily responsible of triggering TLR4/MD-2-dependant innate immune
response by dimerization upon LPS binding. It is well established that, to be activated, TLR4
needs to form a heterodimeric complex with its accessory protein myeloid differentiation factor 2
(MD-2) [150,151]. This TLR4/MD-2 complex will bind to lipopolysaccharide (LPS), a membrane
constituent of Gram-negative bacteria, which leads to the dimerization of two TLR4/MD-2 complexes,
and the final activation of the innate immune system response. As a brief outlook of the interactions,
fatty acid chains for the lipid A moiety of the LPS are recognized and inserted into the hydrophobic
MD-2 pocket, while the polar moieties (sugars, phosphate groups, and polysaccharidic core) interact
with both the rim of MD-2 protein, constituted with polar residues, and some other polar residues
of TLR4 (Figure 3) [152]. These interactions will lead to and stabilize the heterodimerization of the
complex, triggering an intracellular cascade of events leading to the immune response activation.
Therefore, TLR4 has attracted much attention for the discovery of new modulators with important
applications in biomedicine [153].
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prediction accuracy without reducing screening speed. The ENAMINE database collection was 
screened against the TLR4/MD-2 complex of the crystal structure of the human TLR4 TV3 hybrid-
MD-2-Eritoran complex (PDB-ID: 2Z65). The library was clustered to ensure the least possible 
computational work, while keeping as much of the full chemical diversity of the available library as 
possible. A combination of Jarvis-Patrick and Li algorithms [155,156] was used; as well as the 
Tanimoto similarity calculation [27,157–159] with Daylight fingerprints in order to measure the 
distance between the molecules. About 86,000 clusters were isolated. Then, the compounds 
representing the cluster centroids were taken, and an additional filter that matched the molecular 
volume to the binding site was applied. 
Fast molecular docking for the generation of binding poses and subsequent MD simulations 
were performed to rank the ligand poses according to their binding affinities. The hits were profiled 
against a library of 500 representative human proteins as a selectivity filter in order to remove the 
non-specific inhibitors. Finally, as a proof of concept, the compounds were screened against both 
TLR4 and MD-2 to validate the strategy [154]. Two compounds, T5342126 and T6071187 (Table 4), 
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In the search for novel TLR4 modulators, Yin et al. have applied a computational methodology to
the identification of small drug-like inhibitors of TLR4/MD-2 PPIs [154]. The authors have developed
a novel in silico screening methodology incorporating molecular mechanics (MM) and implicit
solvent methods [154] to evaluate binding free energies, in order to improve affinity prediction
accuracy without reducing screening speed. The ENAMINE database collection was screened against
the TLR4/MD-2 complex of the crystal structure of the human TLR4 TV3 hybrid-MD-2-Eritoran
complex (PDB-ID: 2Z65). The library was clustered to ensure the least possible computational
work, while keeping as much of the full chemical diversity of the available library as possible.
A combination of Jarvis-Patrick and Li algorithms [155,156] was used; as well as the Tanimoto
similarity calculation [27,157–159] with Daylight fingerprints in order to measure the distance between
the molecules. About 86,000 clusters were isolated. Then, the compounds representing the cluster
centroids were taken, and an additional filter that matched the molecular volume to the binding site
was applied.
Fast molecular docking for the generation of binding poses and subsequent MD simulations were
performed to rank the ligand poses according to their binding affinities. The hits were profiled against
a library of 500 representative human proteins as a selectivity filter in order to remove the non-specific
inhibitors. Finally, as a proof of concept, the compounds were screened against both TLR4 and MD-2
to validate the strategy [154]. Two compounds, T5342126 and T6071187 (Table 4), were identified
as potential TLR4- and MD-2-specific antagonists, respectively, completely abolishing LPS-induced
activation of signaling. Their biological activity and selectivity were tested in vitro using Akt1 and
nitric oxide in RAW264.7 cells.
In another study, Gobec et al. [160] performed parallel ligand-based and structure-based virtual
screenings in order to identify novel TLR4 antagonists targeting the TLR4/MD-2 interface using the
crystal structure of the human TLR4 TV3 hybrid-MD-2-Eritoran complex (PDB-ID: 2Z65). For both
ligand-based and structure-based virtual screening, they used the ZINC drug-like subset (~11.3 million
drug-like compounds) from the ZINC database [24].
Regarding the ligand-based virtual screening, they used the OMEGA software [45] on the
compound T5342126 (Table 4), a known TLR4 antagonist [160], to generate five query conformers.
ROCS software was then used to compare the database to all query conformers. The single best overlay
hits were ranked according to the TanimotoCombo scoring function [45], considering similarities in the
molecular shape and color of atom types. Thereby, five compounds were identified (ZINC51408124,
ZINC464832, ZINC26905159, ZINC32525142 and ZINC32524933, Table 4) and evaluated in vitro.
Unfortunately, these compounds were either not water soluble, or not active, or presented cytotoxicity
on HEK293 cells.
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(ZINC51408124, ZINC464832, ZINC26905159, ZINC32525142 and ZINC32524933, Table 4) and 
evaluated in vitro. Unfortunately, these compounds were either not water soluble, or not active, or 
presented cytotoxicity on HEK293 cells. 
Table 4. 2D Chemical structure of TLR4 modulators identified by VS techniques and mentioned in 
this review. The database codes are provided. 
TLR4
3D structure from PDB-ID 3FXI 
   
ENAMINE: T5342126 [161] 
TLR4 inhibitor 
ZINC: ZINC04272679 [162] 
Predicted TLR4 inhibitor 
ZINC: ZINC00611718 [162] 
Predicted TLR4 inhibitor 
  
ENAMINE: T6071187 [161] 
MD-2 inhibitor 
ZINC: ZINC04272561 [162] 
Predicted TLR4 inhibitor 
ZINC: ZINC48141941 [162] 
Predicted TLR4 inhibitor 
  
ENAMINE: 5339238 
ZINC: ZINC25778142 [160] 
TLR4 inhibitor 
ZINC: ZINC09535665 [162] 
Predicted TLR4 inhibitor 
ENAMINE: T6969316 
ZINC: ZINC51408124 [160] 
TLR4 activity not determined (solubility problems) 
 
  
ENAMINE: T5458371 
ZINC: ZINC49563556 [160] 
TLR4 inhibitor 
ZINC: ZINC70039563 [162] 
Predicted TLR4 inhibitor 
ZINC: ZINC464832 [160] 
TLR4 activity not determined (cytotoxicity on HEK293 cells) 
  
ENAMINE: T5315798 
ZINC: ZINC3415865 [160] 
TLR4 inhibitor 
ZINC: ZINC29450369 [162] 
Predicted TLR4 inhibitor 
ENAMINE: T6417643 
ZINC: ZINC26905159 [160] 
Predicted TLR4 inhibitor but not active 
 
 
ZINC: ZINC64951618 [162] 
Predicted TLR4 inhibitor 
ZINC: ZINC41124663 [162] 
Predicted TLR4 inhibitor 
ENAMINE: T6280209 
ZINC: ZINC32525142 [160] 
Predicted TLR4 inhibitor but not active 
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abolishing LPS-induced activation of signaling. Their biological activity and selectivity were tested 
in vitro using Akt1 and nitric oxide in RAW264.7 cells. 
In another study, Gobec et al. [160] performed parallel ligand-based and structure-based virtual 
screenings in order to identify novel TLR4 antagonists targeting the TLR4/MD-2 interface using the 
crystal structure of the human TLR4 TV3 hybrid-MD-2-Eritoran complex (PDB-ID: 2Z65). For both 
ligand-based and structure-based virtual screening, they used the ZINC drug-like subset (~11.3 
million drug-like compounds) f om the ZINC databas  [24]. 
Regarding th  ligand-bas d virtual screening, they used the OMEGA software [45] on the 
compound T5342126 (Table 4), a known TLR4 antagonist [160], to generate five query conformers. 
ROCS software was then used to compare the database to all query conformers. The single best 
overlay hits were ranked according to the TanimotoCombo scoring function [45], considering 
similarities in the molecular shape and color of atom types. Thereby, five compounds were identified 
(ZINC51408124, ZINC464832, ZINC26905159, ZINC32525142 and ZINC32524933, Table ) and 
evaluated in vitro. Unfortunately, these compounds were either not wat r soluble, or not active, or 
pr se ted cytot xicity on HEK293 cells. 
T ble 4. 2D Chemical structure of TLR4 modulators identified by VS techniques and mentioned in 
t is review. The database c es are provide . 
TLR4
3D structure from PDB-ID 3FXI 
   
ENAMINE: T5342126 [161] 
TLR4 inhibitor 
ZINC: ZINC04272679 [162] 
Predicted TLR4 inhibitor 
ZINC: ZINC00611718 [162] 
Predicted TLR4 inhibitor 
  
ENAMINE: T6071187 [161] 
MD-2 inhibitor 
ZINC: ZINC04272561 [162] 
Predicted TLR4 inhibitor 
ZINC: ZINC48141941 [162] 
Predicted TLR4 inhibitor 
  
ENAMINE: T5339238 
ZINC: ZINC25778142 [160] 
TLR4 inhibitor 
ZINC: ZINC09535665 [162] 
Predicted TLR4 inhibitor 
ENAMINE: T6969316 
ZINC: ZINC51408124 [160] 
TLR4 activity not determined (solubility problems) 
 
  
ENAMINE: T5458371 
ZINC: ZINC49563556 [160] 
TLR4 inhibitor 
ZINC: ZINC70039563 [162] 
Predicted TLR4 inhibitor 
ZINC: ZINC464832 [160] 
TLR4 activity not determined (cytotoxicity on HEK293 cells) 
  
ENAMINE: T5315798 
ZINC: ZINC3415865 [160] 
TLR4 inhibitor 
ZINC: ZINC29450369 [162] 
Predicted TLR4 inhibitor 
ENAMINE: T6417643 
ZINC: ZINC26905159 [160] 
Predicted TLR4 inhibitor but not active 
 
 
ZINC: ZINC64951618 [162] 
Predicted TLR4 inhibitor 
ZINC: ZINC41124663 [162] 
Predicted TLR4 inhibitor 
ENAMINE: T6280209 
ZINC: ZINC32525142 [160] 
Predicted TLR4 inhibitor but not active 
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abolishing LPS-induced activation of si naling. Their biologi al activity and selectivity were tested 
i  vitro using Akt1 and nitric oxide in RAW264.7 cells. 
In another study, G bec et al. [160] performed parallel ligand-based and structure-based virtual 
screenings in order to identify novel TLR4 antagonists targeting the TLR4/MD-2 interface using the 
crystal stru ture of the human TLR4 TV3 hybrid-MD- -Eritoran complex (PDB-ID: 2Z65). For both 
ligand-based and structur -based virtual screening, they used the ZINC drug-like subset (~11.3 
illi  r g-like compounds) from th  ZINC database [24]. 
Re rding the l gand-bas d virtual scr ening, they used th OMEGA software [45] on the 
compound T5342126 (Table 4),  k own TLR4 antagonis  [160], to generate five query conformers. 
ROCS softwar  was th n used to compare the database to all qu ry conformers. The single best 
overlay hits were rank d ccording to the TanimotoCombo scoring function [45], considering 
similarities in the molecular shape and colo  of atom types. Thereby, five compounds were identified 
(ZINC51408124, ZINC464832, ZINC26905159, ZINC32525142 and ZINC32524933, Table 4) and 
evaluated in vi ro. Unfortunately, thes  compounds were either not w ter soluble, or not active, or 
presented cytotoxicity on HEK293 cells. 
Table 4. 2D Chemical structure of TLR4 modula ors identified by VS techniques and mentioned in 
this revi w. The database codes are provided. 
TLR4
3D structure from PDB-ID 3FXI 
   
ENAMINE: T5342126 [161] 
TLR4 inhibitor 
ZINC: ZINC04272679 [162] 
Predicted TLR4 inhibitor 
ZINC: ZINC00611718 [162] 
Predicted TLR4 inhibitor 
  
ENAMINE: T6071187 [ 61] 
MD-2 inhibitor 
ZINC: ZINC04272561 [162] 
Predicted TLR4 inhibitor 
ZINC: ZINC48141941 [162] 
Predicted TLR4 inhibitor 
  
ENAMINE: T5339238 
ZINC: ZINC25778142 [160] 
TLR4 inhibitor 
ZINC: ZINC09535665 [162] 
Predicted TLR4 inhibitor 
ENAMINE: T6969316 
ZINC: ZINC51408124 [160] 
TLR4 activity n t determined (solubility problems) 
 
  
ENAMINE: T5458371 
ZINC: ZINC49563556 [160] 
TLR4 inhibitor 
ZINC: ZINC70039563 [162] 
Predicted TLR4 inhibi or 
ZINC: ZINC464832 [160] 
TLR4 activity n t determined (cytotoxicity on HEK293 cells) 
  
ENAMINE: T5315798 
ZINC: ZINC3415865 [160] 
TLR4 inhibitor 
ZINC: ZINC29450369 [162] 
Predicted TLR4 inhibitor 
ENAMINE: T6417643 
ZINC: ZINC26905159 [160] 
Predicted TLR4 inhibitor but not active 
 
 
ZINC: ZINC6495 618 [162] 
Predicted TLR4 inhibitor 
ZINC: ZINC41124663 [162] 
Predicted TLR4 inhibitor 
ENAMINE: T6280209 
ZINC: ZINC32525142 [160] 
Predicted TLR4 inhibitor but not active 
ENAMINE: T5342126 [161]
TLR4 inhibitor
ZINC: ZINC 72679 [162]
Predicted TLR4 inhibitor
ZINC: ZIN 6 1718 [162]
Predicted TLR4 inhibitor
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abolishing LPS-induced activation of signaling. Their biological activity and selectivity were tested 
in vitro using Akt1 and nitric oxide in RAW264.7 cells. 
In a other study, Gobec et al. [160] performed parallel li and-b sed and structu -ba d virtual 
screenings  order to identify novel TLR4 antagonists targeting the TLR4/MD-2 interface using the 
crystal structure of the human TLR4 TV3 hybrid-MD-2-Eritoran complex (PDB-ID: 2Z65). For both 
ligand-bas d and st ucture-based virtual screeni g, they used the ZINC drug-like subset (~11.3 
million drug-like compounds) from the ZINC database [24]. 
Regarding the ligand-based virtual screening, they used the OMEGA software [45] on the 
compound T5342126 (Table 4), a known TLR4 antagonist [160], to generate five query conformers. 
ROCS software was then used to compare the database to all query conformers. The single best 
overlay hits were anked accor ing to t  Tanimot Combo scoring function [45], considering 
similarities in the m l cul r shape and col r of atom types. The eby, five compounds w  dentified 
(ZINC51408124, ZINC464832, ZINC26905159, ZINC32525142 and ZINC32524933, Table 4) and 
evaluated in vitro. Unfortunately, these compounds were either not water soluble, or not active, or 
presented cytotoxicity on HEK293 cells. 
Table 4. 2D Chemical structure of TLR4 modulato  entified by VS techniques and m ntioned in 
this review. Th  database codes are provided. 
TLR4
3D structure from PDB-ID 3FXI 
   
ENAMINE: T5342126 [161] 
TLR4 inhibitor 
ZINC: ZINC04272679 [162] 
Predicted TLR4 inhibitor 
ZINC: ZINC00611718 [162] 
Predicted TLR4 inhibitor 
  
ENAMINE: T6071187 [161] 
MD-2 inhibitor 
ZINC: ZINC04272561 [162] 
Predicted TLR4 inhibitor 
ZINC: ZINC48141941 [162] 
Predicted TLR4 inhibitor 
  
ENAMINE: T5339238 
ZINC: ZINC25778142 [160] 
TLR4 inhibitor 
ZINC: ZINC09535665 [162] 
Predicted TLR4 inhibitor 
ENAMINE: T6969316 
ZINC: ZINC51408124 [160] 
TLR4 activity not determined (solubility problems) 
 
  
ENAMINE: T5458371 
ZINC: ZINC49563556 [160] 
TLR4 inhibitor 
ZINC: ZINC70039563 [162] 
Predicted TLR4 inhibitor 
ZINC: ZINC464832 [160] 
TLR4 activity not determined (cytotoxicity on HEK293 cells) 
  
ENAMINE: T5315798 
ZINC: ZINC3415865 [160] 
TLR4 inhibitor 
ZINC: ZINC29450369 [162] 
Predicted TLR4 inhibitor 
ENAMINE: T6417643 
ZINC: ZINC26905159 [160] 
Predicted TLR4 inhibitor but not active 
 
 
ZINC: ZINC64951618 [162] 
Predicted TLR4 inhibitor 
ZINC: ZINC41124663 [162] 
Predicted TLR4 inhibitor 
ENAMINE: T6280209 
ZINC: ZINC32525142 [160] 
Predicted TLR4 inhibitor but not active 
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abolishing LPS-induced activation of sig aling. Their biological activity and selectivity were tested 
in vitro using Akt1 and nitric oxide in RAW264.7 cells. 
In another study, Gobec et al. [160] perform d parallel ligand-based and structure based virtual 
screenin s in order to identify novel TLR4 ant gonists targeting the TLR4/MD-2 interface using the 
crystal structure of the human TLR4 TV3 hybri -MD-2-Eritoran complex (PDB-ID: 2Z65). For both 
ligand-base  and structure-based virtual screening, they used the ZINC drug-like subset (~11.3 
million drug-like compounds) from the ZINC database [24]. 
Reg rdi g the liga d-based virtu l screening, th y used the OMEGA software [45]  the 
compound T5342126 (Table 4), a known TLR4 antagonist [160], to gen rate five query conformers. 
ROCS softw r  was the  used to c pare the database t  all query co f rmers. The single best 
overlay hits we  ranked acc rding to th  Tanim toC b  scoring function [45], consideri g 
similarities in the molecular shape and color of atom types. Thereby, five compounds were identified 
(ZINC51408124, ZINC464832, ZINC26905159, ZINC32525142 and ZINC32524933, Table 4) and 
evaluated in vitro. Unfortunately, these compounds were either not water soluble, or not active, or 
presented cytotoxicity on HEK293 cells. 
Table 4. 2D Chemical structure of TLR4 modulators identified by VS techniques and mentioned in 
this review. The database codes are provided. 
TLR4
3D structure from PDB-ID 3FXI 
   
ENAMINE: T5342126 [161] 
TLR4 inhibitor 
ZINC: ZINC04272679 [162] 
Predicted TLR4 inhibitor 
ZINC: ZINC00611718 [162] 
Predicted TLR4 inhibitor 
  
ENAMINE: T6071187 [161] 
MD-2 inhibitor 
ZINC: ZINC04272561 [162] 
Predicted TLR4 inhibitor 
ZINC: ZINC48141941 [162] 
Predicted TLR4 inhibitor 
  
ENAMINE: T5339238 
ZINC: ZINC25778142 [160] 
TLR4 inhibitor 
ZINC: ZINC09535665 [162] 
Predicted TLR4 inhibitor 
ENAMINE: T6969316 
ZINC: ZINC51408124 [160] 
TLR4 activity not determined (solubility problems) 
 
  
ENAMINE: T5458371 
ZINC: ZINC49563556 [160] 
TLR4 inhibitor 
ZINC: ZINC70039563 [162] 
Predicted TLR4 inhibitor 
ZINC: ZINC464832 [160] 
TLR4 activity not determined (cytotoxicity on HEK293 cells) 
  
ENAMINE: T5315798 
ZINC: ZINC3415865 [160] 
TLR4 inhibitor 
ZINC: ZINC29450369 [162] 
Predicted TLR4 inhibitor 
ENAMINE: T6417643 
ZINC: ZINC26905159 [160] 
Predicted TLR4 inhibitor but not active 
 
 
ZINC: ZINC64951618 [162] 
Predicted TLR4 inhibitor 
ZINC: ZINC41124663 [162] 
Predicted TLR4 inhibitor 
ENAMINE: T6280209 
ZINC: ZINC32525142 [160] 
Predicted TLR4 inhibitor but not active 
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abolishing LPS-induced activation of signaling. Their b ological activi y and sel ctivity were tested 
in vitro using Akt1 and itric oxide in RAW264.7 cells. 
In nother study, Gob c t al. [160] performed parallel li and-based  tructure-bas d virtual 
screenings in order to ide tify nov  TLR4 antagonis s targeting the TLR4/MD-2 interface using the 
crystal str ct re of the human TLR4 TV3 hybrid-MD-2-Eritoran complex (PDB-ID: 2Z65). For both 
ligand-bas d and tructure-ba ed virtual scr e ing, they used the ZINC drug-like subset (~11.3 
m llion drug-like compounds) from the ZINC database [24]. 
R garding the ligand-ba ed virtual screening, they used the OMEGA software [45] on the 
compound T5342126 (Table 4), a known TLR4 antag nist [160], to generate five qu y conformers. 
ROCS software was then used o compare the database to all qu ry conformers. The single best 
overlay hits w re ranked accor i g to he T nimotoC mb  sc ring function [45], con idering 
imilariti  in t  molecul r shap n  col r f at m types. Thereb , f ve comp und  were i ntified 
(ZINC51408124, ZINC464832, ZINC269051 9, ZINC32525142 and ZINC32524933, Tabl  4) and 
e aluated in vitro. Unfortunately, these compounds were either not water soluble, or not active, or 
presented cytotoxicity on HEK293 cells. 
Table 4. 2D Chemical structure of TLR4 modulators identified by VS techniques and mentioned in 
this review. Th  database c des are provided. 
TLR4
3D structure from PDB-ID 3FXI 
   
ENAMINE: T5342126 [161] 
TLR4 inhibitor 
ZINC: ZINC04272679 [162] 
Predicted TLR4 inhibitor 
ZINC: ZINC00611718 [162] 
Predicted TLR4 inhibitor 
  
ENAMINE: T6071187 [161] 
MD-2 inhibitor 
ZINC: ZINC04272561 [162] 
Predicted TLR4 inhibitor 
ZINC: ZINC48141941 [162] 
Predicted TLR4 inhibitor 
  
ENAMINE: 5339238 
ZINC: ZINC25778142 [160] 
TLR4 inhibitor 
ZINC: ZINC09535665 [162] 
Predicted TLR4 inhibitor 
E AMINE: T6969316 
ZINC: ZINC51408124 [160] 
TLR4 activity not determined (solubility problems) 
 
  
ENAMINE: T5458371 
ZINC: ZINC49563556 [160] 
TLR4 inhibitor 
ZINC: ZINC70039563 [162] 
Predicted TLR4 inhibitor 
ZINC: ZINC464832 [160] 
TLR4 activity not determined (cytotoxicity on HEK293 cells) 
  
ENAMINE: T5315798 
ZINC: ZINC3415865 [160] 
TLR4 inhibitor 
ZINC: ZINC29450369 [162] 
Predicted TLR4 inhibitor 
ENAMINE: T6417643 
ZINC: ZINC26905159 [160] 
Predicted TLR4 inhibitor but not active 
 
 
ZINC: ZINC64951618 [162] 
Predicted TLR4 inhibitor 
ZINC: ZINC41124663 [162] 
Predicted TLR4 inhibitor 
ENAMINE: T6280209 
ZINC: ZINC32525142 [160] 
Predicted TLR4 inhibitor but not active 
ENAMINE: 7 187 [ 61]
MD-2 inhibitor
ZINC: ZINC0 2561 [162]
Predicted TLR4 inhibitor
ZINC: ZIN 4194 [162]
Predicted TLR4 inhibitor
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abolishing LPS-i duced activation of signaling. Their biological activity and selectivity were tested 
in vitro using Akt1 and itric oxide in RAW264.7 cells. 
In another tudy, Gobec et al. [160] perfor ed parallel ligand-based and structure-based virtual 
screenings in order to identify n vel TLR4 antagonists targeting the TLR4/MD-2 interface using the 
crystal structure of the human TLR4 TV3 hybrid-MD-2-Eritora  compl x (PDB-ID: 2 65). For both 
ligand-based and structure-based virtual screening, they used the ZINC drug-like subset (~11.3 
million drug-like compounds) from the ZINC database [24]. 
Regarding the ligand-b s d virtu l screening, they used the OMEGA software [45] on the 
compound T5342126 (Table 4), a kn wn TLR4 antagonist [160], t  generate five query confor s. 
ROCS oftware was then used to co pare the atabase to all quer conf r ers. The si gl  best 
overlay hits were r nk d according to the Tanimoto b  scoring function [45] nsidering 
similarities in th  mole ular shape and color of atom types. Thereby, five compou s were iden ified 
(ZINC51408124, ZINC464832, ZINC26905159, ZINC32525142 and ZINC32524933, Table 4) and 
evaluated in vitro. U f rtunately, these compounds were either n t water soluble, or not active, or 
presented cytotoxicity on HEK293 cells. 
Table 4. 2D Chemical structure of TLR4 modulators identified by VS techniques and mentioned in 
this review. The database codes are provided. 
TLR4
3D structure from PDB-ID 3FXI 
   
ENAMINE: T5342126 [161] 
TLR4 inhibitor 
ZINC: ZINC04272679 [162] 
Predicted TLR4 inhibitor 
ZINC: ZINC00611718 [162] 
Predicted TLR4 inhibitor 
  
ENA INE: T6071187 [161] 
MD-2 inhibitor 
ZINC: ZINC04272561 [162] 
Predicted TLR4 inhibitor 
ZINC: ZINC48141941 [162] 
Predicted TLR4 inhibitor 
  
ENAMINE: T5339238
ZINC: ZINC25778142 [160] 
TLR4 inhibitor 
ZINC: ZINC09535665 [162] 
Predicted TLR4 inhibitor 
ENAMINE: T6969316 
ZINC: ZINC51408124 [160] 
TLR4 activity not determined (solubility problems) 
 
  
ENAMINE: T5458371 
ZINC: ZINC49563556 [160] 
TLR4 inhibitor 
ZINC: ZINC70039563 [162] 
Predicted TLR4 inhibitor 
ZINC: ZINC464832 [160] 
TLR4 activity not determined (cy otoxicity on HEK293 cells) 
  
ENAMINE: T5315798 
ZINC: ZINC3415865 [160] 
TLR4 inhibitor 
ZINC: ZINC29450369 [162] 
Predicted TLR4 inhibitor 
ENAMINE: T6417643 
ZINC: ZINC26905159 [160] 
Predicted TLR4 inhibitor but not active 
 
 
ZINC: ZINC64951618 [162] 
Predicted TLR4 inhibitor 
ZINC: ZINC41124663 [162] 
Predicted TLR4 inhibitor 
ENAMINE: T6280209 
ZINC: ZINC32525142 [160] 
Predicted TLR4 inhibitor but not active 
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abolishi g LPS-induced activation of signaling. Their biological activity and selectivity were tested 
in vitro using Akt1 and nitric oxide in RAW264.7 cells. 
In another study, Gobec et . [160] perf rmed parallel ligand-based and ructure-based virtual 
screenings in order to identify novel LR4 antagonists targeting the TLR4/M -2 interface using the 
crystal structure of the h man TLR4 TV3 hybrid-MD-2-Eritoran complex (PDB-ID: 2Z65). For both 
ligand-based and st uct r -based virtual screening, they used the ZINC drug-like ubset (~11.3 
million drug-like compound ) from the ZINC a abase [24]. 
Regardi g the ligand-base  vir ual screening, they used the OMEGA software [45] on the 
compound T5342126 (Table 4), a kn wn TLR4 ant gonist [160], to generate fiv  query conformers. 
ROCS software was then used to compare the database to all query conformers. The si gle best 
overl y hits were ranked accordi g t  the TanimotoCombo scoring function [45], considering 
similarities in the molecular shape and color of atom types. Thereby, five compounds were identifie  
(ZINC51408124, ZINC464832, ZINC26905159, ZINC32525142 a d ZINC32524933, Table 4) and 
evaluate  in vitro. Unf rtunately, these compounds were either not wat r soluble, or not active, or 
presented cytotoxicity on HEK293 cell .
Table 4. 2D Ch mical structu e of TLR4 modulators identified by VS tec  and mentioned in 
this review. The database codes are provided. 
TLR4
 structure from PDB-ID 3FXI 
   
ENAMINE: T5342126 [161] 
TLR4 inhibitor 
ZINC: ZINC04272679 [162] 
Predicted TLR4 inhibitor 
ZINC: ZINC00611718 [162] 
Predicted TLR4 inhibitor 
 
ENAMINE: T6071187 [161] 
MD-2 inhibitor 
ZINC: ZINC04272561 [162] 
Predicted TLR4 inhibitor 
ZINC: ZINC48141941 [162] 
Predicted TLR4 inhibitor 
  
ENAMINE: T5339238 
ZINC: ZINC25778142 [160] 
TLR4 inhibitor 
ZINC: ZINC09535665 [162] 
Predicted TLR4 inhibi or 
ENAMINE: T6969316 
ZINC: ZINC51408124 [160] 
TLR4 activity not determined (solubility problems) 
 
  
ENAMINE: T5458371 
ZINC: ZINC49563556 [160] 
TLR4 inhibitor 
ZINC: ZINC70039563 [162] 
Predic ed TLR4 inhibitor 
ZINC: ZINC464832 [160] 
TLR4 activity not determined (cytotoxicity on HEK293 cells) 
  
ENAMINE: T5315798 
ZINC: ZINC3415865 [160] 
TLR4 inhibitor 
ZINC: ZINC29450369 [162] 
Predicted TLR4 inhibitor 
ENAMINE: T6417643 
ZINC: ZINC26905159 [160] 
Predicted TLR4 inhibitor but not active 
 
 
ZINC: ZINC64951618 [162] 
Predicted TLR4 inhibitor 
ZINC: ZINC41124663 [162] 
Predicted TLR4 inhibitor 
ENAMINE: T6280209 
ZINC: ZINC32525142 [160] 
Predicted TLR4 inhibitor but not active 
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a lis i  S-i ce  acti ati  f si ali . eir i l ical acti it  a  selecti it  ere teste  
i  itr  si  t1 a  itric xi e i  264.7 cells. 
I  a t er st , ec et l. [160] erfor e  arallel li a - ase  a  tr ct re- ase  irt al 
scree i s i  r er t  i e tif  el 4 a ta ists tar eti  t e 4/ D-2 i terface si  t e 
cr stal str ct re f t e u a  4 3 ri - -2- rit ra  c lex ( -I : 2 65). r t  
li a - ase a  str ct r - ase  irt a scree , t e  se  t e I  r -li e s set (~11.3 
illi  r li e c ) fr  t e I  ata ase [24]. 
e ar i  t e li - ased irt l scree i , t  se  t e  s ft are [45]  t e 
c  5342126 ( a le 4), a  4 a ta ist [160], t  erate fi  er  c f r rs. 
S s ft are as t e  se  t  c are t e ata ase t  all er  c f r ers. e sin le est 
erla  its re ra e  acc r i  t  t e a i t  sc ri  f cti  [45], c si eri  
si ilarities i  t e lec lar s a e a  c l r f at  t es. ere , fi e c s ere i e tifie  
( I 51408124, I 464832, I 26905159, I 32525142 an  I 32524933, a le 4) a  
e al at  i  itr . for atel , t ese c s ere eit er t at r s l le, r t acti e, r 
rese te  c t t xicit   293 cells. 
a l  4. 2  h ical tr ct re f 4 o lators i entif e  by S t ues an  entione in 
this revie . he atabase co es are rovi e . 
TLR4
3D structure fro  P B-I  3FXI 
   
E I E: T5342126 [161] 
TLR4 inhibitor 
ZI C: ZI C04272679 [162] 
Predicted TLR4 inhibitor 
ZI C: ZI C00611718 [162] 
Predicted TLR4 inhibitor 
  
E I E: T6071187 [161] 
-2 inhibitor 
ZI C: ZI C04272561 [162] 
Predicted TLR4 inhibitor 
ZI C: ZI C48141941 [162] 
Predicted TLR4 inhibitor 
  
E I E: T5339238 
ZI C: ZI C25778142 [160] 
TLR4 inhibitor 
ZI C: ZI C09535665 [162] 
Predicted TLR4 inh bitor 
E I E: T6969316 
ZI C: ZI C51408124 [160] 
TLR4 activity not deter ined (solubility proble s) 
 
  
E I E: T5458371 
ZI C: ZI C49563556 [160] 
TLR4 inhibitor 
ZI C: ZI C70039563 [162] 
Predicted TLR4 inhibitor 
ZI C: ZI C464832 [160] 
TLR4 activity not deter ined (cytotoxicity on EK293 ce ls) 
  
E I E: T5315798 
ZI C: ZI C3415865 [160] 
TLR4 inhibitor 
ZI C: ZI C29450369 [162] 
Predicted TLR4 inhibitor 
E I E: T6417643 
ZI C: ZI C26905159 [160] 
Predicted TLR4 inhibitor but not active 
 
 
ZI C: ZI C64951618 [162] 
Predicted TLR4 inhibitor 
ZI C: ZI C41124663 [162] 
Predicted TLR4 inhibitor 
E I E: T6280209 
ZI C: ZI C32525142 [160] 
Predicted TLR4 inhibitor but not active 
ENAMI E: T5339238
ZINC: ZINC25778142 [160]
TLR4 inhibitor
ZINC: ZINC09535665 [162]
Predicted TLR4 inhibitor
E AMI E: T6969316
ZINC: ZINC51408124 [160]
TLR4 activity not determined
(solubility problems)
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abolishing LPS-induc d activati n of sig aling. The  bio ogic l activity sel tivity w re tested 
in vitro u ing Akt1 and nitr c oxi e in RAW264.7 cells. 
I  anothe  study, Gobec et al. [160] performed parallel ligand-based and structure-based virtual 
screening  in order o i entify novel TLR4 antago ists targeting t e TLR /MD-2 interface using t e 
crystal st ct re of th  human LR4 TV3 hybri -MD-2-Eritoran complex (PDB-ID: 2Z65). F r both 
ligand-b sed and structure-based virtua  s r ni g, they used he ZIN  drug-lik  subset (~11.3 
illion drug-lik  comp nds) from the ZINC d tab se [24]. 
Regarding the liga d-bas d virtu l s reening, th  u ed th  OMEGA software [45] on th  
compound T 3 2126 (Table ), a k own TLR4 tag nist [ 60], to gen rate five query formers.
ROCS software was then u ed to c mpare the databas  to all query conformers. The single b st 
overlay hits w re ranked according to the TanimotoCombo scoring functio  [45], consideri g 
similarities in the mo cular shape and col r of atom types. Thereby, five compounds were identified 
(ZINC514081 4, ZINC 64832, ZIN 26905159, ZINC32525142 nd ZINC32524933, Tabl  4) and 
evaluated in vitro. Unfortunately, these compoun s w re eith r not water soluble, or not active, or 
presented cytotoxicity on HEK293 cells. 
Table 4. 2D Chemical structure of TLR4 modulators identified by VS techniques and mentioned in 
this review. The database codes are provided. 
TLR4
3D structure from PDB-ID 3FXI 
   
ENAMINE: T5342126 [161] 
TLR4 inhibitor 
ZINC: ZINC04272679 [162] 
Predicted TLR4 inhibitor 
ZINC: ZINC00611718 [162] 
Predicted TLR4 inhibitor 
  
ENAMINE: T6071187 [161] 
MD-2 inhibitor 
I : I 04272561 [162] 
re icte  4 i i it r 
ZINC: ZINC48141941 [162] 
Predicted TLR4 inhibitor 
  
ENAMINE: T5339238 
ZINC: ZINC25778142 [160] 
TLR4 inhibitor 
ZINC: ZINC09535665 [162] 
Predicted TLR4 inhibitor 
ENAMINE: T6969316 
ZINC: ZINC51408124 [160] 
TLR4 activity not determined (solubility problems) 
 
  
ENAMINE: T5458371 
ZINC: ZINC49563556 [160] 
TLR4 inhibitor 
ZINC: ZINC70039563 [162] 
Predicted TLR4 inhibitor 
ZINC: ZINC464832 [160] 
TLR4 activity not determined (cytotoxicity on HEK293 cells) 
  
ENAMINE: T5315798 
ZINC: ZINC3415865 [160] 
TLR4 inhibitor 
ZINC: ZINC29450369 [162] 
Predicted TLR4 inhibitor 
ENAMINE: T6417643 
ZINC: ZINC26905159 [160] 
Predicted TLR4 inhibitor but not active 
 
 
ZINC: ZINC64951618 [162] 
Predicted TLR4 inhibitor 
ZINC: ZINC41124663 [162] 
Predicted TLR4 inhibitor 
ENAMINE: T6280209 
ZINC: ZINC32525142 [160] 
Predicted TLR4 inhibitor but not active 
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abolishing LPS- nd ced ac v ti  of signali g. The r biological acti i  an  selectivity w re te d
n vit o using Akt1 a d nitric oxide in RAW264.7 cells. 
In another study, Gob c et al. [160] p rfo med parallel ligand-bas d nd structure-based virtual
scr enings in order to ide tify n vel TLR4 nta onists targeting the TLR4/ D-2 interface using the 
crys al structure f the human TLR4 TV3 hybrid-MD-2-Eritoran complex (PDB-ID: 2Z65). For b th
ligand-b ed n  structur -b s  virtu l scree i , they used the ZINC drug-like subset (~11.3
mill o  drug-like compou ds) from th ZIN  datab se [24]. 
R g rding the ligan -bas d virtual scre ni g, th y used the OMEGA software [45] on the
co poun T53 21 6 (Table 4), a known TLR  anta o ist [160], to ge erat  five query conformers.
ROCS sof war  was th n used t  compar  t  database to all query c nform rs. The si gle best
erl y hits we e ranked accord ng t  the Ta imotoCombo sc ring fu ction [45], considering
si ilarities in the l cular shape and color f atom types. Thereby, fiv  compo nds were identified 
(ZINC5140 1 4, ZINC464832, ZINC26905159, ZINC32525142 and ZINC32524933, Tabl  4) and 
evalu ed n vitro. Unfortun t ly, these compounds ere either not water soluble, or not active, or 
presented cytotoxicity on HEK293 cells. 
Tab e 4. 2D Chemical struct re f TLR4 mo ulators ident fied by VS t chniques and mentioned in 
this review. The database codes are provided. 
TLR4
3D structure from PDB-ID 3FXI 
   
ENAMINE: T5342126 [161] 
TLR4 inhibitor 
ZINC: ZINC04272679 [162] 
Predicted TLR4 inhibitor 
ZINC: ZINC00611718 [162] 
Predicted TLR  inhibitor 
  
ENAMINE: T6071187 [161] 
MD-2 inhibitor 
ZINC: ZINC04272561 [162] 
Predicted TLR4 inhibitor 
ZINC: ZINC48141941 [162] 
Predicted TLR4 inhibitor 
  
ENAMINE: T5339238 
ZINC: ZINC25778142 [160] 
TLR4 inhibitor 
ZINC: ZINC09535665 [162] 
Predicted TLR4 inhibitor 
ENAMINE: T6969316 
ZINC: ZINC51408124 [160] 
TLR4 activity not determined (solubility problems) 
 
  
ENAMINE: T5458371 
ZINC: ZINC49563556 [160] 
TLR4 inhibitor 
ZINC: ZINC70039563 [162] 
Predicted TLR4 nhibit r 
ZINC: ZINC464832 [160] 
TLR4 activity not determined (cytotoxicity on HEK293 cells) 
  
ENAMINE: T5315798 
ZINC: ZINC3415865 [160] 
TLR4 inhibitor 
ZINC: ZINC29450369 [162] 
Predicted TLR4 inhibitor 
ENAMINE: T6417643 
ZINC: ZINC26905159 [160] 
Predicted TLR4 inhibitor but not active 
 
 
ZINC: ZINC6495 618 [ 62] 
Predicted TLR4 inh bitor 
ZIN : 46 3 [162] 
Pre   inhibitor 
ENAMINE: T6280209 
ZINC: ZINC32525142 [160] 
Predicted TLR4 inhibitor ut not active 
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abolish g LPS-ind c d ctivation of si n ling. Thei  biologi l activity and sel ctivity were t sted 
 vit o using Akt1 a  nit ic oxi  in RAW264.7 cells. 
In another st dy, G ec et al. [160] performed parallel ligand-base  and s ructure-based virtual 
scree ings i  order to i entify novel TLR4 ntagonists targeting t e TLR4/MD-2 interface using t e 
cry al s ruc ure of the hum  TLR4 TV3 hybrid-MD-2-Eritoran complex (PDB-ID: 2Z65). F r both 
liga -based and s ructur -base  virt al scre ni g, they used t  ZINC dr g-like subset (~11.3 
illio  rug-lik  compoun s) fr  the ZINC d ta as [24].
Regar ing th ligand-based virtual scr ening, th y u e th OMEGA oftware [45] on the 
compou d T5342126 (Table 4), a k own TLR4 antagonist [ 60], to gen rat  five query confo mers. 
ROCS software was th n use  to compar the d taba  to all qu ry co fo mers. The single best 
overlay hits were rank d c ording to the TanimotoComb  scoring f nction [45], cons dering 
similarities in the mo ecula  sh pe and colo  f atom types. Thereby, five omp u s were id nt fied 
(ZINC514081 4, ZINC464832, ZINC26905159, ZINC32525142 and ZINC32524933, Tabl  4) and 
evalu t d n vi ro. Unfort nately, thes  compounds w re ither not w ter soluble, r not active, or 
presented cytotoxicity on HEK293 cells. 
Table 4. 2D Chemical structure of TLR4 modula ors identified by VS techniques and mentioned in 
this revi w. The d tabase cod s are provided. 
TLR4
3D structure from PDB-ID 3FXI 
   
ENAMINE: T5342126 [161] 
LR4 inhibitor 
ZINC: ZINC04272 79 [162] 
Predicted TLR4 inhibitor 
ZINC: ZINC0061 718 [162] 
Predicted TLR4 inhibitor 
  
ENAMINE: T607 187 [ 61] 
MD-2 inhibitor 
I : I 04272561 [162] 
re icte  4 i i it r 
ZINC: ZINC48 4 941 [162] 
Predicted TLR4 inhibitor 
  
ENAMINE: T5339238 
ZINC: ZINC25778142 [160] 
TLR4 inhibitor 
ZINC: ZINC09 35 65 [162] 
Predicted TLR4 inhibitor 
ENAMINE: T6969316 
ZINC: ZINC51 08124 [160] 
TLR4 activity n t det rmined (solubility problems) 
 
  
ENAMINE: T5458371 
ZINC: ZINC49563556 [160] 
TLR4 inhibitor 
ZINC: ZINC70039563 [162] 
Predicted TLR4 inhibi or 
ZINC: ZINC464832 [160] 
TLR4 activity n t det rmined (cytotoxicity on HEK293 cells) 
  
ENAMINE: T5315798 
ZINC: ZINC3415865 [160] 
TLR4 inhibitor 
ZINC: ZINC29450369 [162] 
Predicted TLR4 inhibitor 
ENAMINE: T6417643 
ZINC: ZINC26 05159 [160] 
Predicted TLR4 inhibitor but not active 
 
 
ZINC: ZINC 495 18 [162] 
Predicted TLR4 inhibitor 
INC: ZINC 1124 3 [162] 
Predicted TLR4 inhibitor 
ENAMIN : 09 
ZINC: ZIN  [160] 
Predicted TLR4 i i it r t not active 
ENAMINE: T5 58371
ZINC: ZINC49563556 [160]
TLR4 inhibitor
ZINC: ZINC70039563 [162]
Predicted TLR4 inhibitor
INC: ZIN 64832 [160]
TLR4 activit not determined
(cytotoxicity on HEK293 cells)
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abolishing LPS-induce  activa on f signaling. T  i logical ctivity and selectivity were test d 
in vitro using Akt1 and itric oxide in RAW264.7 c ll . 
In another tudy, Gobec et al. [160] performed parallel ligand-based and structure-based virtual 
screeni gs in order to i entify novel TLR4 antagonists ta g ti  the TLR4/MD-2 interface sing the 
crystal structure of he h ma  TLR4 TV3 hybrid-MD-2-Eritoran complex (PDB-ID: 2Z65). For both 
ligand-b sed and struct re-b sed virtual s r ening, th y used t ZINC drug-like s b et (~11.3 
million drug-like compou d ) fro  the ZINC database [2 ]. 
Regar ing the ligand-based virtual screeni g, th y used the OMEGA software [45] on t  
compound T5342126 (Table 4), a known TLR4 antagonist [160], to generate five query conformers. 
ROCS software was then used to compare the atabase to all qu ry conformers. The single best 
overlay hits were ranked according to the TanimotoCombo scoring function [45], considering 
similarities in the olecular shape and color of atom types. Thereby, fiv  comp unds wer  identified 
(ZINC514081 , 464832, ZINC26905159, ZIN 325 5142 and ZINC 2524933, Table 4) and 
evaluated in i nfortunat ly, th s  mp unds wer  ither not wat r solubl , or not ctiv , or 
presented cyt t icit on HEK 93 ells.
Table 4. 2D Chemical structure of TLR4 modulators identified by VS techniques and mentioned in 
this review. The database codes are provided. 
TLR4
3D structure from PDB-ID 3FXI 
   
ENAMINE: T5342126 [161] 
TLR4 inhibitor 
ZINC: ZINC04272679 [162] 
Predicted TLR4 inhibitor 
ZINC: ZINC00611718 [162] 
Predicted TLR4 inhibitor 
  
ENAMINE: T6071187 [161] 
M -  i i itor 
ZINC: ZINC04272561 [162] 
Predicted TLR4 inhibitor 
ZINC: ZINC48141941 [162] 
Predicted TLR4 inhibitor 
  
ENAMINE: T5339238 
ZINC: ZINC25778142 [160] 
TLR4 inhibitor 
ZINC: ZINC09535665 [162] 
Predicted TLR4 inhibitor 
ENAMINE: T6969316 
ZINC: ZINC51408124 [160] 
TLR4 activity not determined (solubility problems) 
 
  
ENA I : 458371 
ZINC: ZINC495635 6 [160] 
TL 4 i i itor 
ZINC: ZINC7 03 563 [162] 
Predicted TLR4 inhibitor 
ZINC: ZINC464832 [160] 
TLR4 activity not determined (cytot icity on HEK293 cells) 
  
ENAMINE: T5315798 
ZINC: ZINC3415865 [160] 
TLR4 inhibitor 
ZINC: ZINC29450369 [162] 
Pr icted TLR4 inhibitor 
ENAMINE: T6417643 
I C: ZINC269 5159 [160] 
Predicted TLR4 inhibitor but not active 
 
 
ZINC: ZINC64951618 [162] 
Predicted TLR4 inhibitor 
ZINC: ZINC41124663 [162] 
Predicted TLR4 inhibitor 
ENAMINE: T6280209 
ZINC: ZINC32525142 [160] 
Predicted TLR4 inhibitor but not active 
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abolishing LPS- nduced activation of signal ng. Their biological activi y a  l c ivity were tested 
in vitro using Akt1 and nitric oxide in RAW264.7 cells. 
In another study, Gobec t al. [160] performed parallel ligand-based and structure-based virtual 
screenings in order t  identify novel TLR4 antago is s targeting the TLR4/MD-2 terface using the 
crystal str ct re of the h ma  TL   yb id-MD-2-Eritora  complex (P B-ID: 2Z65). For both 
liga -based d st uctur -base l sc ning, th y used the ZINC dr g like subset (~11.3 
m llion d u - ke c mpo nds) fro  t  I C at base [24].
R gardi g the lig d-b sed virtu l screenin , they us d the OMEGA software [45] on the 
compound T5342126 (Table 4), a known TLR4 a tagonist [160], to generate five query co formers. 
ROCS software was then used to compare the database to all query conformers. The single best 
overlay hits were ranked according to he Tanimot Combo scoring fun tion [45], consideri g 
similarities in the molecular shape and color of atom types. Thereby, five compounds were identified 
(ZINC51408124, ZINC4 4832, ZINC269051 9, ZINC32525142 and ZINC32524933, Table 4) and 
evaluat d in vitro. Unfortunately, the e c mpou ds were ei her not wat r s lubl , or not activ , or 
presented cytotoxicity on HEK293 c lls. 
Table 4. 2D Chemical structure of LR4 modulators identified by VS techniques and mentioned in 
t is review. The database co s are provided. 
TLR4
3D structure from PDB-ID 3FXI 
   
ENAMINE: T5342126 [161] 
TLR4 inhibitor 
ZINC: ZINC04272679 [162] 
Predicted TLR4 inhibitor 
ZINC: ZINC00611718 [162] 
Predicted TLR4 inhibitor 
  
ENAMINE: T6071187 [161]
MD-2 inhibitor 
ZINC: ZI C04272561 [162] 
Predicted TLR4 inhibitor 
ZINC: ZINC48141941 [162] 
Predicted TLR4 inhibitor 
  
ENAMINE: T5339238 
ZINC: ZINC25778142 [160] 
TLR4 inhibitor 
ZINC: ZINC09535665 [162] 
Predicted TLR4 inhibitor 
ENAMINE: T6969316 
ZINC: ZINC51408124 [160] 
TLR4 activity n t determined (solubility problems) 
 
  
ENAMINE: T5458371 
ZINC: ZINC49563556 [160] 
TLR4 inhibitor 
ZINC: I C70039563 [1 2] 
Predicted TLR4 inhib tor 
ZINC: ZINC464832 [160] 
TLR4 activity not determined (cytotoxicity on HEK293 cells) 
  
ENAMINE: 5315798 
ZINC: ZINC3415865 [160] 
TLR4 inhibitor 
ZINC: ZINC29450369 [162] 
Predicted TLR4 inhibitor 
ENAMINE: T6417643 
ZINC: ZINC26905159 [160] 
Predicted TLR4 inhibit  t ot active 
 
 
ZINC: ZINC64951618 [162] 
Predicted TLR4 inhibitor 
ZINC: ZINC41124663 [162] 
Predicted TLR4 inhibitor 
ENAMINE: T6280209 
ZINC: ZINC32525142 [160] 
Predicted TLR4 inhibitor but not active 
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a lis i  -i ce  acti ati  f si ali . eir l ical act i  nd s l cti it re teste  
i  itr  i  t1 a  itric i  i  264.7 cells. 
I  a t er st , ec t al. [160] erf r e  arallel li - ase  a  tr ct re- ase  irt al 
scree i s i  r er to i e tif el 4 a ta is s tar eti  t  4/ -2 int rface si  t e 
cr stal str ctur  f t e u   3 h ri - -2- rit ra  c le  ( -I : 2 65). r t  
li and- se   tr t r - a irtual sc i , t e  se  t e I  -li  s set (~11.3 
lli r -li e co u s) fr  t e ZIN  d ta ase [24]. 
ar in  t e li a - a e  irt al scree i g, t e  se  t   s ft are [45]  t e 
c  5342126 ( a le 4), a  4 ta ist [160], t  e erate fi e  f r ers. 
 s ft are as t e  e   c are t e ata ase t  all r  c f r ers.  si le st 
erla  its ere ra e  acc r i  t  e a i to  sc ri  f cti  [45], c si erin  
si il riti s i  t e lec lar s a e  c l r f at  t es. ere , fi e c s ere i e tifie  
( I 51408124, I 4 832, I 2690 9, I 32525142 a  I 32524933, a le 4) a  
e al t  r . f rt atel , t  co n e it t t r sol l , r t acti e, r 
rese te c t t icit   293 cells.
a l  4. 2  e ical str ct re of T 4 o lators i e tifie  by S tec iq es a  e tio e  i  
this revie . e atabase codes are rovi e . 
TLR4
3  structure fro  P B-I  3FXI 
   
E I E: T5342126 [161] 
TLR4 inhibitor 
ZI C: ZI C04272679 [162] 
Predicted TLR4 inhibitor 
ZI C: ZI C00611718 [162] 
Predicted TLR4 inhibitor 
  
E I E: T6071187 [161] 
-2 inhibi or
ZI C: ZINC04272561 [162] 
Predicted TLR4 inhibitor 
ZI C: ZI C48141941 [162] 
Predicted TL 4 inhibitor 
  
E I E: T5339238 
ZI C: ZI C25778142 [160] 
TLR4 inhibitor 
ZI C: ZI C09535665 [162] 
Predicted TLR4 inh bitor 
E I E: T6969316 
ZI C: ZI C51408124 [160] 
TLR4 activity not deter ined (solubility proble s) 
 
  
E I E: T5458371 
ZI C: ZI C49563556 [ 60] 
TLR4 inhibitor 
ZI C: ZINC70039563 [162] 
Predicted TLR4 inhibitor 
ZI C: ZI C464832 [160] 
TLR4 activity n t deter ined (cytotoxicity on EK293 ce ls) 
  
E I E: 5315798 
ZI C: ZI C3415865 [160] 
TLR4 inhibitor 
ZI C: ZI C29450369 [162] 
Predicted TLR4 inhibitor 
E I E: T6417643 
ZI C: ZI 2690 159 [160] 
Predicted TLR4 i t r but not active 
 
ZI C: ZI C64951618 [162] 
Predicted TLR4 inhibitor 
ZI C: ZI C41124663 [162] 
Predicted TLR4 inhibitor 
E I E: T6280209 
ZI C: ZI C32525142 [160] 
Predicted TLR4 inhibitor but not active 
ENAMI E: T5315798
ZINC: ZINC3415865 [160]
TLR4 inhibitor
ZINC: ZINC29 50369 [162]
Predicted T 4 inhibitor
ENAMIN 6417643
ZI C: ZINC 6905159 [160]
Predicted TLR4 inhibitor but not
active
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abolishing LPS-i duc d activation of signaling. Their biologic l activity and s lectivity were tested 
in vitro u ing Akt1 and nitric oxi e in RAW264.7 cells. 
I  ano her study, Gob c et l. [160] perfor ed parallel lig nd-based and structure-based virtual 
screenings in order to i entify novel TLR4 antagonists targeti  t  TLR4/MD-2 interface using t  
rystal structure of the human TLR4 TV3 hybrid-MD-2-Eritoran complex (PDB-ID: 2Z65). F r both 
ligand-based and structu -based virt al scre ning, th y used th  ZINC drug-like subset (~11.3 
million drug-like compound ) from the ZINC d tabase [24]. 
Rega ing the l g d based virt al sc eni g, h y used th  OMEGA software [45] on th  
compound T5342126 (T ble 4), a k own TLR4 n gonist [ 60], to generat  fiv  query conformer . 
ROCS software was then used to comp r  the databas  to all qu ry conformers. The singl  best 
ov rlay hits were ranked according to the TanimotoCombo scoring function [45], considering 
similarities in the molecular shape and color of atom types. Thereby, five compounds were identified 
(ZINC51408124, ZIN 64832, ZINC26905159, ZINC32525142 and ZINC32524933, Tabl  4) and 
evaluated in vitro. Unfortunately, the  ompounds were either not water soluble, or not active, or 
presented cytotoxici y on HEK293 cells. 
Table 4. 2 ical structur of TLR4 modulat rs identified by VS t chniques and m ntioned in 
this revie .  ataba  codes ar provid d. 
TLR4
3D structur  from PDB-ID 3FXI 
   
ENAMINE: T5342126 [161] 
TLR4 i ibitor 
ZINC: ZINC04272679 [162] 
Predicted TLR4 inhibitor 
ZINC: ZINC00611718 [162] 
Predicted TLR4 inhibitor 
  
ENAMINE: T6071187 [161] 
D-2 inhibitor 
I : I 04272561 [162] 
Predicted TL 4 inhibitor 
ZINC: ZINC48141941 [162] 
Predicted TLR4 inhibitor 
  
ENAMINE: 5339238 
ZINC: ZINC25778142 [160] 
TLR4 inhibitor 
ZINC: ZINC09535665 [162] 
Predicted TLR4 inhibitor 
ENAMINE: T6969316 
ZI : ZINC51408124 [160] 
TLR4 activity ot de erm ned (solubility problems) 
 
  
ENA INE: T5458371 
ZINC: ZINC495635 6 [160] 
TL  itor 
ZINC: ZINC70039563 [162] 
Predicted TLR4 inhibitor 
ZINC: ZINC464832 [160] 
TLR4 activity not determined (cytotoxicity on HEK293 cells) 
  
ENAMINE: T5315798 
ZINC: ZINC3415865 [160] 
TLR4 inhibitor 
ZINC: ZINC29450369 [162] 
Predicted TLR4 inhibitor 
ENAMINE: T6417643 
ZINC: ZINC26905159 [160] 
Predicted TLR4 inhibitor but not active 
 
 
ZINC: ZINC64951618 [162] 
Predicted TLR4 inhibitor 
ZINC: ZINC41124663 [162] 
Predicted TLR4 inhibitor 
ENAMINE: T6280209 
ZINC: ZINC32525142 [160] 
Predicted TLR4 inhibitor but not active 
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abolishi g LPS- nduced activation of signa ng. Th ir b o ogic l a tivi y  s l c ivity were ested 
i  vitro using Akt1 an nitric oxid  i  RAW264.7 cells. 
In another st dy, Gob c t al. [160] perfo med p ral l ligand-based and tructure-based virtual 
screenings in order t  identify novel TLR4 antagonis s targeting t  TLR4/MD-2 i terface using t  
crystal struct re of the human TLR4 TV3 hyb id-MD-2-Eritoran compl x (PDB-ID: 2Z65). F r both 
ligan -based and tructure-ba ed virtu l scre ning, the  used the ZINC dru -like subset (~11.3 
m llion dr g-like compo nds) from the ZIN  atabase [24]. 
R ga i  t ligand-based virtual scre nin , they s d the OMEGA oftware [45] on the 
compound T5342126 (Tab 4),  know TLR4 antag nist [160], to en rate five query conform rs. 
ROCS software was then used to compar  th  database to all q ery conf rmers. The single best 
ov rlay hits were ranked according to he Tanimot Combo scoring fun tion [45], considering 
similarities in the molecular shape and color of atom types. Thereby, five compounds were identified 
(ZINC514081 4, ZINC464832, ZINC269051 9, ZINC32525142 and ZINC32524933, Tabl  4) and 
aluated in vitro. Unfortunately, these compounds were ei her not water s luble, or not active, or 
presented cytotoxicity on HEK293 c lls. 
Table 4. 2D Ch mical structu e of  odulators identified by VS tec i  and mentioned in 
t is revi w. Th  dat base co s ar  i ed. 
TLR4
3D structure from PDB-ID 3FXI 
  
ENAMINE: T5342126 [161] 
TLR4 inhibitor 
ZINC: ZINC04272679 [162] 
Predicted T 4 inhibitor 
ZINC: ZINC00611718 [162] 
Predicted R4 inhibitor 
 
ENAMINE: T6071187 [161] 
MD-2 inhibitor 
I : I 04272561 [162] 
re icte  4 inhibitor 
ZINC: ZINC48141 41 [ 2] 
Predicted TLR  inhibitor 
  
ENAMINE: T5339238 
ZINC: ZINC25778142 [16 ] 
TLR4 inhib tor 
ZINC: ZINC09535665 [162] 
Predicted TLR4 inhibitor 
ENAMINE: T6969316 
ZINC: ZINC51408124 [160] 
TLR4 act vity not determined (solubility problems) 
 
  
ENAMINE: T5 58371 
ZINC: ZINC49563556 [160] 
TLR4 inhibitor 
ZINC: ZINC70039563 [162] 
Predicted TLR4 inhib tor 
ZINC: ZINC464832 [160] 
TLR4 activity not determined (cytotoxicity on HEK293 cells) 
  
ENAMINE: T5315798 
ZINC: ZINC3415865 [160] 
TLR4 inhibitor 
ZINC: ZINC29450369 [162] 
Predicted TLR4 inhibitor 
ENAMINE: T6417643 
ZINC: ZINC26905159 [160] 
Predicted TLR4 inhibitor but not active 
 
 
ZINC: ZINC64951618 [162] 
Predicted TLR4 inhibitor 
ZINC: ZINC41124663 [162] 
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In another work, Sowdhamini et al. [162] used homology modeling, docking, and virtual 
screening techniques, in combination with known experimental data, molecular mechanics 
calculation to identify novel and potential small molecule inhibitors of TRAM-mediated TLR4 
signaling. For this purpose, they identified TLR10 TIR dimer as the best model to build the TIR 
domain of TLR4 as a dimer. Then, they modeled the C-terminal region of the A46 poxviral protein 
containing the VIPER motif, using the crystal structure of A52 poxviral protein (PDB-ID: 2VVW) as a 
template. This motif is capable of binding the TIR domain of different adaptor proteins. After having 
obtained the two models, they performed a two-phase docking for creating reliable models of the 
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For the structure-based virtual screening, before the docking process, they performed an enriching
procedure, using ROCS software between the database and T5342126, the query molecule, in order
to reduce the number of compound and to enrich it. Two sets of 25,000 compounds each were
created: set 1 with the highest shape similarities to T5342126, using ShapeTanimoto algorithm [163],
and set 2 with both the highest shape and color (atom type) similarities to T5342126, using the
TanimotoCombo algorithm [164]. Both sets were merged and the duplicates were removed, leading
to a total of 49,600 unique compounds left. The docking procedure was carried out using FlexX
program and the active site was defined as an area of TLR4 within 8 Å around the interacting MD-2
loop (Gly97-Leu108). LeadIT-implemented pharmacophore constraints were performed then in order
to keep only the compounds that can form interactions with at least one of the polar amino-acid
residues such as Ser183 and Asp209 of TLR4, and Arg106 of MD-2 (Figure 4). At the end of the
implementation, 25,750 compounds had been kept, and the docking procedure was performed.
The compounds have been finally ranked according to their best scoring conformation using LeadIT
score and 40 were selected and assessed in vitro. After the first in vitro assay, only 14 compounds were
sufficiently water-soluble, up to 500 µM, and completely non-cytotoxic at 100 µM. Those received
further biological evaluation using HEK-BlueTM hTLR4 cells, and three compounds with promising
antagonistic activities were discovered: ZINC25778142, ZINC49563556 and ZINC3415865.
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template. This motif is capable of binding the TIR domain of different adaptor proteins. After having 
obtained the two models, they performed a two-phase docking for creating reliable models of the 
Figure 4. 3D structure representation of the extracellular domain of the TLR4/MD-2 complex with
Eritoran (PDB-ID: 2Z65) focused on the interaction surfaces between TLR4 (yellow), and MD-2 (orange).
Polar amino-acid residues used to perform the docking procedure are shown in sticks.
In another work, Sowdhamini et al. [162] used homology modeling, docking, and virtual screening
techniques, in combination with known experimental data, molecular mechanics calculation to identify
novel and potential small molecule inhibitors of TRAM-mediated TLR4 signaling. For this purpose,
they identified TLR10 TIR dimer as the best model to build the TIR domain of TLR4 as a dimer.
Then, they modeled the C-terminal region of the A46 poxviral protein containing the VIPER motif,
using the crystal structure of A52 poxviral protein (PDB-ID: 2VVW) as a template. This motif is capable
of binding the TIR domain of different adaptor proteins. After having obtained the two models, they
performed a two-phase docking for creating reliable models of the complex between the TRAM TIR
homology model and the VIPER peptide segment. A virtual screening was then performed on the
complex. They used the lead-like and drug-like subsets of the ZINC database, totaling 32 million
compounds. The ligands 2D structures were converted into their 3D structure including all possible
stereoisomers, tautomers, and ionization states under a pH range of 6–8. Then, the hydrogens were
added and the structures were optimized and minimized in LigPrep. The library was preliminary
screened based on ADMET properties and reactive functional groups, using Qikprop [165] and
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Lipinski’s rule of five [21]. The amino acid residues constituting the BB loop (110–122) and alphaC
helix (141–154) of the TLR4 TIR domain were selected to generate the receptor grid.
Glide was used for the docking by concatenating the three protocols: HTVS, SP and XP. The top
10% compounds, based on the Glide score, obtained from the HTVS step were retained for the
subsequent step. These were re-docked using the SP module. The XP module was used to perform a
more extensive docking of the top 10% compounds carried forward from the SP step. Final ranking
of the compounds was based on their Glide XP Score. The compounds having similar scaffold were
then clustered using CANVAS [166,167] resulting in a pool of 265 chemically diverse structures.
These selected compounds were submitted to induce fit docking within the Maestro suite [168–170]
to restrict the flexibility only into the binding site. For this purpose, they used the Glide SP protocol
to generate 2000 poses for each molecule within the binding site. Finally, they inspected the top
20 receptor-ligand poses for each ligand to see if potential interaction between the binding site residues
and the ligand atoms were maintained or disrupted upon incorporating flexibility to the residues, and
the ligands with more interactions conserved throughout most of the poses were selected. Binding free
energy calculations were performed on the top two poses generated during induced-fit docking of
each compound. These complexes between the TRAM TIR homology model and each ligand were
ranked according to this analysis and a final structural analysis of the ligand/receptor interactions
was performed, shortlisting 12 molecules (Table 4). Interestingly, compound ZINC08687988 remained
firmly bound in the pocket even after incorporating a considerable degree of conformational flexibility
during the MD simulations carried out in the complexes. To date, no further biological testing has
been performed yet.
4.4. Virtual Screening Studies in TLR7
Toll-like receptor 7 (TLR7) is intracellularly located at the membranes of endosomes, endoplasmic
reticulum, multivesicular bodies, and lysosomes [171]. Its function is related to defense against
viral infection by recognizing single-stranded RNA (ssRNA) and small-interfering RNA (siRNA)
from viruses [172,173], including human immunodeficiency virus, influenza, and vesicular stomatitis
virus [174]. The host can also utilize TLR7 to detect RNA released into endolysosomes by
phagosomal bacteria. Several synthetic ligands have also been reported to modulate TLR7, such
as imidazoquinoline derivatives (resiquimod and imiquimod), and guanine analogues [175]. Also,
TLR7 recognizes guanosine- and uridine-rich ssRNA, and synthetic polyuridines act as potent
ligands [173]. The development of new antagonist modulators could have important applications for
the treatment of autoimmune disorders, like rheumatoid arthritis, Sjogren’s syndrome, and systemic
lupus erythematosus [176].
Since no X-ray crystallographic structure of TLR7 is available to date, in order to identify TLR7
modulators, Gobec et al. undertook a ligand-based VS [65]. ROCS was employed to carry out the
screening protocol from which six compounds with three novel chemical scaffolds were discovered.
The authors employed ZINC database and OMEGA software to prepare the compound library. With the
help of ROCS, two query compounds were identified as TLR7 binders: query 1 (imiquimod) and query
2 (1-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)-2-methylpropan-2-ol) (Table 3). Imiquimod
(query 1) is a TLR7 agonist currently used for topical treatment of genital warts caused by human
papillomavirus, actinic keratosis, and superficial basal cell carcinoma [177], and query 2 compound was
developed in the last years in a systematic SAR exploration study as the most potent imidazoquinoline
with TLR7 agonist activity [178].
From queries 1 and 2, the authors performed parallel VS studies. The results were ranked taking
into account the TanimotoCombo score, and the best results from both VS were finally merged. The best
25 ranked compounds were selected and submitted to biological assays, only considering soluble
and available compounds. Cytotoxicity tests were performed with HEK-BlueTM hTLR7 determined
using a propidium-iodide based staining method and none of the compounds showed cytotoxicity
at 250 µM. In the subsequent step, the soluble compounds were assayed for TLR7 agonist activity at
Int. J. Mol. Sci. 2016, 17, 1508 24 of 34
250 and 500 µM using the reporter assay but none of the compounds showed any notable agonist
activity. Finally, to evaluate the antagonist activity, the compounds were tested using HEK239 cell
line co-transfected with hTLR7 gene using imiquimod as a control. Six compounds were identified as
antagonists at the µM scale containing three novel chemical scaffolds: chromeno[3,4-d]imidazole-4-one,
1H-imidazo[4,5-d]pyridazine-4,7-dione, and 6-amino-9H-purine (ZINC codes 12382420, 1667204, 39698,
36416, 4756232, and 8686004, Table 3). The authors also propose a simple and straightforward
synthesis of derivatives from the chromeno[3,4d]imidazole-4-one scaffold which showed promising
TLR7 antagonistic activities.
4.5. Virtual Screening Studies in TLR8
Toll-like receptor 8 (TLR8) is an endosomal membrane receptor that recognizes single stranded
RNA (ssRNA) from viruses. TLR8 [179] is expressed in monocytes and myeloid dendritic cells [180,181].
TLR8 signaling pathways are mediated by MyD88; this adaptor protein activates NF-κB, IRF-7, and
p38 MAPK, resulting in the induction of pro-inflammatory cytokines such as TNF-α, IL-6, IL-1β,
IL-12, and antiviral type I interferons. Therefore, TLR8 is a promising target in the development
of vaccine adjuvants and anticancer agents [182]. The 3D structure is well-known and six X-Ray
crystallographic structures of human TLR8 in complex with six agonists are available (PDB-ID: 3W3J,
3W3K, 3W3N, 3WN4, 4Q8Z, and 4QC0) [183–185]. TLR8 consists of an extracellular domain with
a horseshoe-shape containing 26 LRR modules, with the ssRNA binding site being very large and
flexible. Ligand binding induces reorganization of the pre-organized TLR8 dimer finally enabling
downstream signaling processes [183].
To overcome the difficulty of targeting a flexible binding site, Pei et al. [166,167] have performed
an enrichment assessment of multiple virtual screening methods, and developed a combined
strategy to improve the performance of virtual screening for TLR8 agonists. First, they have
created a knowledge-based pharmacophore (KBP) by merging structure-based pharmacophore and
previous SAR analysis including furo[2,3-c]pyridines, furo[2,3-c]quinoles, thiazolo[4,5-c]quinolones,
3-R-quinolone-2-amine, and C7-methoxycarbonyl-imidazoquines. The combination of the KBP
screening with ROCS search was used to improve the efficiency of the virtual screening process.
The authors prepared a benchmarking data set merging 13 known active compounds [186–189],
15 known inactive compounds, and decoys from ZINC database [22]. So, finally, they had
13 actives and 1302 decoys. The benchmarking data set was generated from their recently developed
MUBD-Decoymaker protocol [50].
The six TLR8 crystal structures were used to generate SB pharmacophores and shape-based 3D
similarity search queries by means of LigandScout software. Eight pharmacophore models were
derived with similar backbones in agreement with reported SAR for TLR8 agonists: three hydrophobic
centroids, two aromatic rings, one H-bond donor, and one H-bond acceptor. The eight KBPs were used
to screen the benchmarking data set in order to select the most robust KBP. The authors selected the
so-called “Phar1” as the priority KBP and reserved it for the subsequent antagonist verification.
In order to perform an antagonist verification data set to test the agonist/antagonist selectivity
of their selected KBP, 20 reported antagonists were used [178]. For the shape-based 3D similarity
search, the authors performed ROCS queries through the alignment of the six ligands from the six
crystal structures, using TanimotoShape and TanimotoCombo scores. Among the resulting queries, the
so-called “Query4” was further analyzed because of its excellent performance. As an additional step
in the protocol, a comparative study was performed with four docking programs: AutoDock VINA,
GOLD, Surflex-Dock and Glide. Cross-docking runs were performed with 20 cognate ligands and five
dimer TLR8 complexes. Average and median RMSD values were statistically analyzed to determine
which program and which crystal structure best matched VS. Taken together, GOLD was identified
as the most suitable docking program in conjunction with PDB-ID: 3W3J for the VS evaluation of
the protocol.
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Finally, the selected pharmacophore “Phar1” was combined with the ROCS “Query4” in different
ways to get to the best performance as VS strategy for TLR8 agonists. Final docking with GOLD and
PDB-ID: 3W3J, led to the screening of seven compounds, being three of them known active ligands
as TLR8 agonists. The authors conclude that this “Phar1_Q4_Gold” strategy was proved to be a
promising practice for the identification of novel TLR8 agonists. Indeed, this computational effort can
be of help for the design of efficient VS strategies in other TLRs.
5. Conclusions
Each designed virtual screening protocol internalizes the knowledge and intuition of the
researcher devoted to the work, making each of these approaches almost unique. This review intends
to summarize the recently reported (successful) efforts in the search for novel chemical entities with
drug-like properties for TLR modulation by means of VS techniques. This work can serve as inspiration
for further optimization studies, as well as for fostering this active research field seeking novel drugs
for the treatment of severe diseases in which TLR modulation has emerged as a novel therapeutic
strategy. Also, this review provides a descriptive overview of the main databases and computational
techniques employed for VS approaches.
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